Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use

ABSTRACT

A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is related to U.S. provisional Ser. No. 61/982,585,filed Apr. 22, 2014, entitled “INTERIOR ENERGY-ACTIVATION OFPHOTO-REACTIVE SPECIES INSIDE A MEDIUM OR BODY USING AN X-RAY SOURCEEMITTING LOW ENERGY X-RAYS AS INITIATION ENERGY SOURCE”, the entirecontents of which are hereby incorporated by references. Thisapplication is related to provisional Ser. No. 62/096,773, filed: Dec.24, 2014, entitled “ INTERIOR ENERGY-ACTIVATION OF PHOTO-REACTIVESPECIES INSIDE A MEDIUM OR BODY USING AN X-RAY SOURCE EMITTING LOWENERGY X-RAYS AS INITIATION ENERGY SOURCE,” the entire contents of eachof which is incorporated herein by reference. This application isrelated to U.S. provisional Ser. No. 62/132,270, filed Mar. 12, 2015,entitled “TUMOR IMAGING WITH X-RAYS AND OTHER HIGH ENERGY SOURCES USINGAS CONTRAST AGENTS PHOTON-EMITTING PHOSPHORS HAVING THERAPEUTICPROPERTIES”, the entire contents of which are hereby incorporated byreferences. This application is related to U.S. provisional Ser. No.62/147,390, filed Apr. 14, 2015, entitled “TUMOR IMAGING WITH X-RAYS ANDOTHER HIGH ENERGY SOURCES USING AS CONTRAST AGENTS PHOTON-EMITTINGPHOSPHORS HAVING THERAPEUTIC PROPERTIES”, the entire contents of whichare hereby incorporated by references.

This application is related to provisional U.S. Ser. No. 12/401,478 (nowU.S. Pat. No. 8,376,013) entitled “PLASMONIC ASSISTED SYSTEMS ANDMETHODS FOR INTERIOR ENERGY-ACTIVATION FROM AN EXTERIOR SOURCE, filedMar. 10, 2009, the entire contents of which are incorporated herein byreference. This application is related to U.S. Ser. No. 13/102,277entitled “ADHESIIVE BONDING COMPOSITION AND METHOD OF USE,” tiled May 6,2011, the entire contents of which are incorporated herein by reference.This application is related to provisional Ser. No. 61/035,559, filedMar. 11, 2008, entitled “SYSTEMS AND METHODS FOR INTERIORENERGY-ACTIVATION FROM AN EXTERIOR SOURCE,” the entire contents of whichare hereby incorporated herein by reference. This application is relatedto provisional Ser. No. 61/030,437, filed Feb. 21, 2008, entitled“METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USINGPLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPSI) AND EXCITON-PLASMONENHANCED PHOTOTHERAPY (EPEP),” the entire contents of which are herebyincorporated herein by reference. This application is related tonon-provisional Ser. No. 12/389,946, tiled Feb. 20, 2009, entitled“METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS USINGPLASMONICS ENHANCED PHOTOSPECTRAL THERAPY (PEPST) AND EXCITON-PLASMONENHANCED PHOTOTHERAPY (EPEP),” the entire contents of which are herebyincorporated herein by reference. This application is related tonon-provisional Ser. No. 11/935,655, filed Nov. 6, 2007, entitled“METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION RELATED DISORDERS,”and to provisional Ser. No. 60/910,663, filed Apr. 8, 2007, entitled“METHOD OF TREATING CELL PROLIFERATION DISORDERS,” the contents of eachof which are hereby incorporated by reference in their entireties. Thisapplication is related to provisional Ser. No. 61/035,559, filed Mar.11, 2008, entitled “SYSTEMS AND METHODS FOR INTERIOR ENERGY-ACTIVATIONFROM AN EXTERIOR SOURCE,” the entire contents of which are herebyincorporated herein by reference. This application is also related toprovisional Ser. No. 61/792,125, filed Mar. 15, 2013, entitled “INTERIORENERGY-ACTIVATION OF PHOTO-REACTIVE SPECIES INSIDE A MEDIUM OR BODY,”the entire contents of which are hereby incorporated herein byreference. This application is further related to provisional Ser. No.61/505,849 filed Jul. 8, 2011, and U.S. application Ser. No. 14/131,564,filed Jan. 8, 2014, each entitled “PHOSPHORS AND SCINTILLATORS FOR LIGHTSTIMULATION WITHIN A MEDIUM,” the entire contents of each of which isincorporated herein by reference. This application is related to andU.S. application Ser. No. 14/206,337, filed Mar. 12, 2014, entitled“INTERIOR ENERGY-ACTIVATION OF PHOTO-REACTIVE SPECIES INSIDE A MEDIUM ORBODY.” the entire contents of which are hereby incorporated herein byreference. This application is related to national stagePCT/US2015/027058 filed Apr. 22, 2015, entitled “TUMOR IMAGING WITHX-RAYS AND OTHER HIGH ENERGY SOURCES USING AS CONTRAST AGENTSPHOTON-EMITTING PHOSPHORUS HAVING THERAPEUTIC PROPERTIES,” the entirecontents of which are hereby incorporated herein by reference. Thisapplication is related U.S. Ser. No. 62/243,465 filed Oct. 19, 2015,entitled “X-RAY PSORALEN ACTIVATED CANCER THERAPY (X-PACT),” the entirecontents of which are hereby incorporated herein by reference.

This application is related to and claims priority to U.S. Ser. No.62/290,203 filed Feb. 2, 2016, entitled “PHOSPHOR-CONTAINING DRUGACTIVATOR, SUSPENSION THEREOF, SYSTEM CONTAINING THE SUSPENSION, ANDMETHODS FOR USE” and U.S. Ser. No. 62/304,525 filed Mar. 7, 2016,entitled “PHOSPHOR-CONTAINING DRUG ACTIVATOR, SUSPENSION THEREOF, SYSTEMCONTAINING THE SUSPENSION, AND METHODS FOR USE” (the entire contents ofboth U.S. provisional applications are incorporated herein byreference).

BACKGROUND OF THE INVENTION Field of Invention

The invention relates to methods and systems for treating cellproliferation disorders, that provide better distinction between normal,healthy cells and those cells suffering a cell proliferation andpreferably that can be performed using non-invasive or minimallyinvasive techniques.

Discussion of the Background

Light modulation from a deeply penetrating radiation like X-ray opensthe possibility for activating bio-therapeutic agents of various kindswithin mammalian bodies. As an example, the binding of psoralen to DNAthrough the formation of monoadducts is well known to engender an immuneresponse if done properly. Psoralen under the correct light activationgains the aptitude to bind to DNA. Psoralen has been reported to reactto other sites that have a suitable reactivity including and not limitedto cell walls. If this reaction is of the correct kind, as is the casefor psoralen-DNA monoadducts formation, the binding leads to aprogrammable cell death referred to as Apoptosis. Such programmable celldeath, if accomplished over a cell population, can signal the body tomount an immune response permitting target specific cell kill throughoutthe body. Such immune response is of importance for various medicaltreatments including cancer treatment.

Psoralens are naturally occurring compounds found in plants(furocoumarin family) with anti-cancer and immunogenic properties. Theyfreely penetrate the phospholipid cellular bilayer membranes andintercalate into DNA between nucleic acid pyrimidines, where they arebiologically inert (unless photo-activated) and ultimately excretedwithin 24 hours. However psoralens are photo-reactive, acquiring potentcytotoxicity after ‘activation’ by ultra-violet (UVA) light. Whenphoto-activated, psoralens form mono-adducts and di-adducts with DNAleading to marked tumor cytotoxicity and apoptosis. Cell signalingevents in response to DNA damage include up-regulation of p21^(wal/Cip)and p53 activation, with mitochondrial induced cytochrome c release andconsequent cell death. Photo-activated psoralen can also induceapoptosis by blocking oncogenic receptor tyrosine kinase signaling, andcan affect immunogenicity and photochemical modification of a range ofcellular proteins in treated cells.

Importantly, psoralen can promote a strong long-term clinical response,as observed in the treatment of cutaneous T Cell Lymphoma utilizingextracorporeal photopheresis (ECP). fir ECP malignant CTCL cells areirradiated with ultraviolet A (UVA) light in the presence of psoralen,and then re-administered to the patient. Remarkably, complete long termresponses over many decades have been observed in a sub-set of patients,even though only a small fraction of malignant cells were treated. Inaddition to ECP, psoralens have also found wide clinical applicationthrough PUVA treatment of proliferative skin disorders and cancerincluding psoriasis, vitiligo, mycosis fungoides, and melanoma.

The cytotoxic and immunogenic effects of psoralen are often attributedto psoralen mediated photoadduct DNA damage. A principle mechanismunderlying the long-term immunogenic clinical response likely derivesfrom psoralen induced tumor cell cytotoxicity and uptake of theapoptotic cells by immature dendritic cells, in the presence ofinflammatory cytokines. However, photochemical modification of proteinsand other cellular components can also impact the antigenicity andpotential immunogenicity of treated cells. The diversity and potency ofpsoralen application is further illustrated by recent success usingpsoralen in the development of virus vaccines.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a phosphor-containingdrug activator comprising an admixture of two or more phosphors, whichinclude Zn₂SiO₄:Mn^(2°) and (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺) at aratio from 1:10 to 10:1, wherein each of the two phosphors have at leastone coating selected from the group consisting of an ethylene cellulosecoating and a diamond-like carbon coating. The admixture is preferablyin dry solid/powder form.

In one embodiment, there is provided a suspension of thephosphor-containing drug activator. The suspension at least includes twoor more phosphors capable of emitting ultraviolet and visible light uponinteraction with x-rays. The two or more phosphors include Zn₂SiO₄:Mn²⁺and (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺) at a ratio from 1:10 to 10:1, andeach of the two phosphors have at least one coating selected from thegroup consisting of an ethylene cellulose coating and a diamond-likecarbon coating. The suspension further includes a pharmaceuticallyacceptable carrier.

In one embodiment, there is provided a system for treating a disease ina subject in need thereof The system includes a) the above-notedsuspension, b) a photoactivatable drug comprising 8 MOP or UV ALEXuntethered from the two or more phosphors, c) one or more devices whichinfuse the photoactivatable drug and the suspension including thepharmaceutically acceptable carrier into a diseased site in the subject,and d) an x-ray source which is controlled to deliver a dose of x-raysto the subject for production of the ultraviolet and visible lightinside the subject to activate the photoactivatable drug and induce apersistent therapeutic response, said dose comprising a pulsed sequenceof x-rays delivering from 0.5-2 Gy to the tumor.

In further embodiments, there are provided methods for treating adisease in a subject in need thereof using the phosphor-containing drugactivator, either in its dry admixture form or its suspension form. Onemethod includes a) infusing the photoactivatable drug and the suspensionincluding the pharmaceutically acceptable carrier into a diseased sitein the subject, and b) delivering a dose of x-rays to the subject forproduction of the ultraviolet and visible light inside the subject toactivate the photoactivatable drug and induce a persistent therapeuticresponse, said dose comprising a pulsed sequence of x-rays deliveringfrom 0.5-2 Gy to the tumor. A further method includes a) hydrating thedry admixture of the phosphor-containing drug activator, b) combiningthe hydrated form of the phosphor-containing drug activator with thephotoactivatable drug, with the combining either being subsequent to thehydrating or simultaneously with the hydrating, and c) delivering a doseof x-rays to the subject for production of the ultraviolet and visiblelight inside the subject to activate the photoactivatable drug andinduce a persistent therapeutic response, said dose comprising a pulsedsequence of x-rays delivering from 0.5-2 Gy to the tumor.

It is to be understood that both the foregoing general description ofthe invention and the following detailed description are exemplary, butare not restrictive of the invention.

BRIEF DESCRIPTION OF THE FIGURES

A more complete appreciation of the invention and many of the attendantadvantages thereof will be readily obtained as the same becomes betterunderstood by reference to the following detailed description whenconsidered in connection with the accompanying drawings, wherein:

FIG. 1A illustrates a system according to one exemplary embodiment ofthe present invention;

FIG. 1B is a flow diagram for one process of the invention formanufacturing the phosphor-containing device;

FIG. 2 is a depiction of cathodoluminescence data for Zn₂SiO₄:Mn²⁺measured between 100-400 nm;

FIG. 3 is a depiction of cathodoluminescence data for Zn₂SiO₄:Mn²⁺measured between 450-700 nm;

FIG. 4 is a depiction of cathodoluminescence data for (3Ca₃(PO₄)₂.Ca(F,Cl)₂: Sb³⁺, Mn²⁺) measured between 100-400 nm;

FIG. 5 is a depiction of cathodoluminescence data for (3Ca₃(PO₄)₂.Ca(F,Cl)₂: Sb³⁺, Mn²⁺ measured between 450-700 nm;

FIG. 6 is an illustration of a combination phosphor device having a dualcoating;

FIG. 7 is an illustration of a combination phosphor device having a 2:1ratio with one part of Zn₂SiO₄:Mn²⁺ for every two parts of(3Ca₃(PO₄)₂.Ca(F, Cl)₂: Sb³⁺;

FIG. 8 is a photographic depiction of a packaged device kit according toone embodiment of the invention;

FIGS. 9A, 9B, 9C, 9D, and 9E show graphs showing tumor volume as afunction of days after treatment for an in-vivo treatment of BALBC micewith syngeneic 4TI-HER2 tumors, as well as photographs of tumors beingtreated during the course of treatment;

FIG. 10 is a plot summarizing the fractional cell kills as a function ofkVp for a fixed amperage of 200 mA;

FIG. 11 is a photographic depiction showing of methylene blue stainingfor cell viability post treatment with x-rays, phosphors, and UVADEX;

FIG. 12 is a plot summarizing the fractional cell kills under differentx-ray exposure cycles;

FIGS. 13A, 13B, 13C, and 13D illustrate the efficacy of a treatmentin-vitro against 4TI-HER2 cells;

FIGS. 14A and 14B are illustrations of the relative effectiveness of LIVactivated psoralen on three independent cell lines;

FIGS. 15A and 15B are illustrations of the anti-tumor effects of thex-ray psoralen activated cancer therapy (XPACT) treatment and individualcomponents on 4T1-HER2 cells;

FIG. 16 is a comparison of the phosphor-containing drug activator at twodifferent x-ray energies (80 and 100 kVp) for 4T1-HER2 cells treatedwith 8-MOP;

FIGS. 17A and 17B are photographic depictions showing the efficacy ofthe phosphor-containing drug activator during a canine studypre-treatment and post-treatment on Subject #1, respectively; and

FIGS. 18A and 18B are further photographic depictions showing theefficacy of the phosphor-containing drug activator during the caninestudy pre-treatment and post-treatment on Subject #2, respectively.

DETAILED DESCRIPTION OF THE INVENTION

The present invention sets forth a novel method of treating cellproliferation disorders that is effective, specific, and has fewside-effects.

As used herein, the phrase “cell proliferation disorder” refers to anycondition where the growth rate of a population of cells is less than orgreater than a desired rate under a given physiological state andconditions. Although, preferably, the proliferation rate that would beof interest for treatment purposes is faster than a desired rate, slowerthan desired rate conditions may also be treated by methods of theinvention. Exemplary cell proliferation disorders may include, but arenot limited to, cancer, bacterial infection, immune rejection responseof organ transplant, solid tumors, viral infection, autoimmune disorders(such as arthritis, lupus, inflammatory bowel disease, Sjogrenssyndrome, multiple sclerosis) or a combination thereof, as well asaplastic conditions wherein cell proliferation is low relative tohealthy cells, such as aplastic anemia. Particularly preferred cellproliferation disorders for treatment using the present methods arecancer, staphylococcus aureus (particularly antibiotic resistant strainssuch as methicillin resistant staphylococcus aureus or MRSA), andautoimmune disorders.

Those cells suffering from a cell proliferation disorder are referred toherein as the target cells. A treatment for cell proliferationdisorders, including solid tumors, is capable of chemically bindingcellular nucleic acids, including but not limited to, the DNA ormitochondrial DNA or RNA of the target cells. For example, aphotoactivatable agent, such as a psoralen or a psoralen derivative, isexposed in situ an energy source (e.g., x-rays) capable of activatingenergy modulation agents (e.g., phosphors) which emit light to activatephotoactivatable agents such as psoralen or coumarin.

The terminology used in the description of the invention herein is forthe purpose of describing particular embodiments only and is notintended to be limiting of the invention. As used in the description ofthe embodiments of the invention and the appended claims, the singularforms “a”_(;) “an” and “the” are intended to include the plural forms aswell, unless the context clearly indicates otherwise. Also, as usedherein, “and/or” refers to and encompasses any and all possiblecombinations of one or more of the associated listed items. Furthermore,the terms “at” or “about,” as used herein when referring to a measurablevalue or metric is meant to encompass variations of 20%, 10%, 5%, 1%,0.5%, or even 0.1% of the specified amount, for example a specifiedratio, a specified thickness, a specified phosphor size, or a specifiedwater contact angle. It will be further understood that the terms“comprises” and/or “comprising,” when used in this specification,specify the presence of stated features, integers, steps, operations,elements, and/or components, but do not preclude the presence oraddition of one or more other features, integers, steps, operations,elements, components, and/or groups thereof.

The present invention utilizes x-ray driven activation of 8MOP (orUVADEX) to induce a persistent anti-tumor response and a resultingarrest of tumor growth or regression. As used herein, a persistentantitumor response is a response which slows or stops the tumor growthfrom that of a control or blind subject receiving only a placebo. Thepresent invention demonstrates that x-ray driven activation of aphotoactivatable drug (e.g., 8 MOP) slows tumor growth in some cases andin other cases arrests growth of the tumor leading to signs of completeremission for the subject.

In particular, the present invention utilizes a novelphosphor-containing drug activator for causing a change in activity in asubject that is effective, specific, and able to produce a change to themedium or body. The phosphor-containing drug activator comprises amixture of two different phosphors, which upon x-ray excitation, eachhave emissions in the UV and visible spectrum. The mixture of phosphorsresults in superior performance compared to either phosphor alone. Themixture of phosphors preferably includes a mixture of two or morephosphors, namely NP-200 and GTP-4300, that are purchased from Nichiaand Global Tungsten and Powders, respectively. The chemical formulas ofthese phosphors are Zn₂SiO₄:Mn²⁺ and (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺),respectively. These phosphors absorb penetrating forms of energy (e.g.,low dose x-rays) and emit light in wavelengths that activate the 8 MOP(or UVADEX) in-situ. In one embodiment of the invention, the phosphorsin the novel phosphor-containing drug activator are coated with abiocompatible Ethyl Cellulose coating and/or coated with a Diamond LikeCarbon (DLC) coatings. The coatings are described below.

Reference will now be made in detail to the present preferredembodiments of the invention, examples of which are illustrated in theaccompanying drawings (including color drawings), in which likereference characters refer to corresponding elements.

FIG. 1A illustrates a system according to one exemplary embodiment ofthe invention. Referring to FIG. 1A, an exemplary system according toone embodiment of the invention may have an initiation energy source 1directed at the subject 4. An activatable pharmaceutical agent 2 and theabove-noted phosphor-containing drug activator 3 can be administered tothe subject 4 by way of a sterile suspension of two or more of theabove-noted phosphors. The initiation energy source may additionally becontrolled by a computer system 5 that is capable of directing thedelivery of the initiation energy (e.g., X-rays), In furtherembodiments, dose calculation and robotic manipulation devices (such asthe CYBER-KNIFE robotic radiosurgery system, available from Accuray, orsimilar types of devices) may be included in the system to adjust thedistance between the initiation energy source 1 and the subject 4 and/orto adjust the energy and/or dose (e.g., kVp or filtering) of theinitiation energy source such that the x-rays incident on the targetsite are within a prescribed energy band. Further refinements in thex-ray energy and dose can be had by adjusting the distance to thesubject 4 or the intervening materials between the target site and theinitiation energy source 1. The initiation energy source 1 (i.e., anX-ray source) can provide images of the target area being treated.

In various embodiments, the initiation energy source 1 may be a linearaccelerator equipped with at least kV image guided computer-controlcapability to deliver a precisely calibrated beam of radiation to apre-selected coordinate. One example of such linear accelerators is theSMARTBEAM™ IMRT (intensity modulated radiation therapy) system (fromVarian Medical Systems, Inc., Palo Alto, Calif.) or Varian OBItechnology (OBI stands for “On-board Imaging”, and is found on manycommercial models of Varian machines). In other embodiments, theinitiation energy source 1 may be commercially available components ofX-ray machines or non-medical X-ray machines, X-ray machines thatproduce from 10 to 150 keV X-rays are readily available in themarketplace. For instance, the General Electric DEFINIUM series or theSiemens MULTIX series are two non-limiting examples of typical X-raymachines designed for the medical industry, while the EAGLE PACK seriesfrom Smith Detection is an example of a non-medical X-ray machine.Another suitable commercially available device is the SIEMENS DEFINITIONFLASH, (a CT system), by Siemens Medical Solutions. As such, theinvention is capable of performing its desired function when used inconjunction with commercial X-ray equipment.

In a particularly preferred embodiment, the initiation energy source 1is a source of low energy x-rays, of 300 kVp or lower, e.g., at or below300 kVp, at or below 200 kVp, at or below 120 kVp, at or below 105 kVp,at or below 80 kVp, at or below 70 kVp, at or below 60 kVp, at or below50 kVp, at or below 40 kVp, at or below 30 kVp, at or below 20 kVp, ator below 10 kVp, or at or below 5 kVp, In this embodiment, theinitiation energy source provides low energy x-rays which are convertedby the phosphor-containing drug activator 3 in situ to an energy capableof activating 8 MOP (or UVADEX).

In one embodiment of the invention, the phosphors in thephosphor-containing drug activator are first coated with a biocompatibleEthyl Cellulose coating, and then overcoated with a second coating ofDiamond Like Carbon (DLC).

Ethyl Cellulose (EC) is widely used in biomedical applications today,including artificial kidney membranes, coating materials for drugs,blood coagulants, additives of pharmaceutical products, blood compatiblematerials. EC and its derivatives have been widely used in various,personal care, food, biomedical and drug related applications. EC is nota skin sensitizer, it is not an irritant to the skin, and it is notmutagenic. EC is generally regarded as safe (GRAS), and widely used forexample in food applications such flavor encapsulation, inks for makingfruits and vegetables, paper and paperboard in contact with aqueous andfatty foods.

EC is also widely used for controlled release of active ingredients. Theenhanced lipophilic and hydrophobic properties make it a material ofchoice for water resistant applications. EC is soluble in variousorganic solvents and can form a film on surfaces and around particles(such as phosphors). In one embodiment of this invention, ethylcellulose is used to encapsulate the phosphors particles of thephosphor-containing drug activator to ensure that an added degree ofprotection is in place on the surface of the phosphors. In oneembodiment of this invention, EC polymers with high molecular weight forpermanent encapsulation and long term biocompatibility are used toencapsulate the phosphors particles of the phosphor-containing drugactivator. In a preferred embodiment, the EC polymer can be anycommercially available pharmaceutical grade ethyl cellulose polymerhaving sufficient molecular weight to form a coating on the phosphorsurface. Suitable EC polymers include, but are not limited to, theETHOCEL brand of ethyl cellulose polymers available from Dow Chemical,preferably ETHOCEL FP grade products, most preferably ETHOCEL FP 100.

Diamond Like Carbon (DLC) films are in general dense, mechanically hard,smooth, impervious, abrasion resistant, chemically inert, and resistantto attack by both acids and bases they have a low coefficient offriction, low wear rate, are biocompatible and thromboresistant. Tissuesadhere well to carbon coated implants and sustain a durable interface.In presence of blood, a protein layer is formed which prevents theformation of blood clots at the carbon surface. For medical prosthesesthat contact blood (heart valves, anathomic sheets, stents, bloodvessels, etc.), DIX coatings have been used.

DLC has emerged over the past decade as a versatile and usefulbiomaterial. It is harder than most ceramics, bio-inert, and has a lowfriction coefficient. DLC is one of the best materials for implantableapplications. Studies of the biocompatibility of DLC demonstrate thatthere is no cytotoxicity and cell growth is normal on a DLC-coatedsurface. (DLC coatings on stainless steel have performed very well in invitro studies of hemocompatibility, Histopathological investigationshave shown good biotolerance of implants coated with the DLC. Moreover,DLC as a coating is efficient protection against corrosion. Theseproperties make the embodiment described here with a double coating (ECand DLC) particularly advantageous for the novel phosphor-containingdrug activator of the invention.

Methods for coating the phosphors with EC or DLC are known to those ofordinary skill, and have been described, for example, inPCT/US2015/027058 filed Apr. 22, 2015, incorporated earlier byreference.

Manufacturing Process Steps

FIG. 1B is a flow diagram for one process of the invention formanufacturing the novel phosphor-containing drug activator using the rawmaterials noted in Table 1 below. (The present invention is not limitedto the various steps described below in the illustrative manufacturingprocess. The steps merely provide specific ways that these steps canoccur

TABLE 1 Raw Materials Item Description/Name Manufacturer Phosphor GTP4300 Global Tungsten and Powders Phosphor NP200 Nichia Ethyl CelluloseDow Chemical Co Acetone Thermo Fisher Diamond like carbon (DLCFraunhoffer

As shown in FIG. 1B, manufacturing of the novel phosphor-containing drugactivator of the invention starts with quality control of the rawmaterials. As part of quality control, in one embodiment of theinvention, the raw materials utilized in the novel phosphor-containingdrug activator are characterized with one or more of the following suiteof tests:

-   -   X-Ray Diffraction (XRD) to confirm the crystallography type;    -   X-Ray Photoelectron Spectroscopy (XPS) for surface elemental        analysis;    -   Inductively Coupled Plasma (ICP) for total elemental analysis;    -   Scanning Electron Microscopy (SEM) for particle size        determination;    -   Cathodoluminescence for UV/VIS emissions

X-ray diffraction (XRD) is nondestructive technique for characterizingcrystalline materials. It provides information on structures, phases,preferred crystal orientations (texture), and other structuralparameters, such as average grain size, crystallinity, strain, andcrystal defects. The x-ray diffraction pattern is a fingerprint ofperiodic atomic arrangements in a given material. A comparison of anobserved diffraction pattern to a known reference material allowsconfirmation of the crystal lattice of the solid material. In oneembodiment of the invention, x-ray diffraction peaks matching knownreferences form one acceptance criterion of the invention for furtherprocessing. Preferably, the Zn₂SiO₄:Mn²⁺ phosphor has cathodoluminescentemission peaks at least at 160 nm, 360 nm, and 525 nm, while preferablythe (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a cathodoluminescentemission edge at least at 400 nm and a cathodoluminescent emission peakat least at 570 nm.

X-ray Photoelectron Spectroscopy (XPS Analysis), also known as ElectronSpectroscopy for Chemical Analysis (ESCA), is used to determinequantitative atomic composition and chemistry. It is a surface analysistechnique with a sampling volume that extends from the surface to adepth of approximately 50-70 Angstroms. XPS analysis can be utilized tocharacterize thin films by quantifying matrix-level elements as afunction of depth. XPS is an elemental analysis technique that is uniquein providing chemical state information of the detected elements, suchas distinguishing between sulfate and sulfide forms of the elementsulfur. The process works by irradiating a sample with monochromaticx-rays, resulting in the emission of photoelectrons whose energies arecharacteristic of the elements within the sampling volume. In oneembodiment of the invention, XPS is another acceptance criterion of theinvention for further processing in which both the position (energy) ofthe emitted photoelectrons and their relative intensity patterns shouldmatch the reference patterns on file for each inorganic phosphor beingused (e.g. NP200 and GTP430).

In one embodiment of the invention, this analytical method is used todetermine the surface elemental composition of the raw material(s) andsubsequent changes in atomic % of carbon to confirm that both the EC andDLC coating processes are within acceptable tolerances (e.g. up to a25-75% increase in C content for the final EC/DLC autoclave product). Asan acceptance criterion of the invention, emission peaks from Zn, Si,Ca, P, O, F, Cl, Sb, Mn and C should be present and no other elements(such as contaminants) would be present.

Inductively Coupled Plasma (ICP) analytical techniques canquantitatively measure the elemental content of a material from the pptto the wt % range. In this technique, solid samples are dissolved ordigested in a liquid, usually an acidic aqueous solution. The samplesolution is then sprayed into the core of an inductively coupled argonplasma, which can reach temperatures of approximately 8000° C. At suchtemperature, analyte species are atomized, ionized and thermallyexcited. The analyte species is then detected and quantified with a massspectrometer (MS). In one embodiment of the invention, XPS is anotheracceptance criterion of the invention in which both the mass number andintensity (relative quantity) should match reference patterns on filefor each inorganic phosphor used (e.g. NP200 and GTP430).

Scanning Electron Microscopy (SEM) provides high-resolution andlong-depth-of-field images of the sample surface and near-surface, SEMis one of the most widely used analytical tools due to the extremelydetailed images it can provide. Coupled to an auxiliary EnergyDispersive X-ray Spectroscopy (EDS) detector, SEM also offers elementalidentification for nearly the entire periodic table. In one embodimentof the invention, SEM/EDS screens raw and final materials for gross sizeand morphological particle analysis as well as a confirmation ofelemental surface analysis of both our raw and processed materials. Inone embodiment of the invention, SEM and/or EDS is another acceptancecriterion of the invention in which the range of crystal sizes and/orelemental constituency is confirmed.

Cathodoluminescence is a technique that detects light emissions based onthe specific chemistry of a crystalline lattice structure,Cathodoluminescence accelerates and collimates an electron beam toward amaterial (e.g., a phosphorous material). When the incident beam impactsthe material, it causes the creation of secondary electrons and holeformation, the recombination of which leads to the emission of photonswhich are detected by a photospectrometer placed in close proximity tothe material.

In one embodiment of the invention, a representative phosphor containedin the novel phosphor-containing drug activator would be tested byplacing 10 mg inside a high vacuum chamber. The electron beam would beaccelerated using a bias voltage of 1000V to 1500V. Obtaining at least5000 counts (au) ensures that the material is emitting properly, andforms another acceptance criterion of the invention. Referencecathodoluminescence data for raw material phosphors are illustrated inFIGS. 2-5. FIG. 2 is a depiction of cathodoluminescence data forZn₂SiO₄:Mn²⁺ measured between 100-400 nm. FIG. 3 is a depiction ofcathodoluminescence data for Zn₂SiO₄:Mn²⁺ measured between 450-700 nm.FIG. 4 is a depiction of cathodoluminescence data for (3Ca₃(PO₄)₂.Ca(F,Cl)₂: Sb³⁺, Mn²⁺) measured between 100-400 nm. FIG. 5 is a depiction ofcathodoluminescence data for (3Ca₃(PO₄)₂.Ca(F, Cl)₂: Sb³⁺, Mn²⁺ )measured between 450-700 nm. In one embodiment of the invention, thecathodoluminescence emission wavelength of UV and visible light emitted.form an acceptance criterion of the invention.

The above described analytical testing is performed on purchasedphosphors before these materials are accepted for use in manufacturingof the novel phosphor-containing drug activator. The test methods forthe acceptance of the various raw materials in a preferred embodimentare specified below in Table 3.

TABLE 3 Acceptance Criteria for Raw Materials Parameter Method Phosphorcrystalline XRD phase Surface elemental XPS composition Core elementalICP composition Emission CL Size distribution SEM

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator starts processing of the qualifiedraw phosphor materials by washing of the phosphor materials. Morespecifically, in one example, the phosphor materials are individuallyweighed with one gram (1 g) of phosphor placed in 50 mL plastic testtubes. Six mL of acetone are added and vortexed to thoroughly mix withthe phosphors. The phosphors are pelletized via a low speed centrifuge,after which the excess acetone is removed. This cycle is repeated anadditional two times for each of the two phosphors.

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator then coats each of the two phosphorsfirst with ethyl cellulose, followed by a second coating consisting ofdiamond like carbon. Each of the phosphors constituting the phosphorcontaining device in one embodiment of the invention is independentlydoubly coated, before mixing the two phosphors together. FIG. 6 is anillustration of both phosphors (NP-200: Zn₂SiO₄:Mn²⁺ and GTP-4300:(3Ca₃(PO₄)₂.Ca(F, Cl)₂: Sb³⁺, Mn²⁺ coated with a first coating(Ethyl-Cellulose) and a second coating (Diamond-Like-Carbon).

For the ethyl-cellulose coating, in one preferred embodiment of theinvention, the phosphor particles are encapsulated based on theparameters provided in Table 4.

TABLE 4 Preferred thickness of the EC coating Ethyl Cellulose CoatingTarget Thickness (nanometers) 30 Phosphor Density (g/cc) 7.5

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator in one embodiment of the inventionthen coats each of the two phosphors with a secondary coat of DLC byPhysical Vapor Deposition to further encapsulate the phosphors and tofurther enhance their biocompatibility.

For the DLC film, a preferred thickness is 100 nm +/−3 nm, and apreferred Elastic Modulus is 45-55 Gpa, most preferably 50-53 Gpa.

The PVD coating machine is equipped with various process control sensorsand interlocks to ensure reproducibility.

The contact angle of non-coated glass and non-coated silicon are 19degrees and 65 degrees respectively. After the coating process, thecontact angles are preferably 100° +/−10%. The contact angle (for awater droplet) of both substrates is targeted to be between 90 and 110°.The water droplet contact angle provides another acceptance criterion ofthe invention.

Specific release specifications for in-process testing are specified inthe table below:

TABLE 7 Release Specifications for In-Process Test Material ParameterMethod Coating thickness Step Height Size distribution Scanning Surfaceelemental XPS composition

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator in one embodiment of the inventioncontinues by mixing the two types of coated phosphors. Thephosphor-containing drug activator as noted above is made of acombination of two phosphors. Specifically, NP-200 (Zn₂SiO4:Mn²⁺) ismixed with GTP-4300 (3Ca3(PO4)2.Ca.(F, Cl)2: Sb3+, Mn2+) at a ratioNP-200:GTP-4300 of from 1:10 to 10:1, or from 1:5 to 5:1, or from 1:2 to2:1, or about 1:2.

FIG. 7 is a representative illustration of the mixture of phosphorsconstituting the phosphor-containing device. (The efficacy of thismixture has been determined in vitro by assessing the cell kill broughtabout by the addition of the drug alone, mixture of phosphors alone, andthen the mixture of drug and phosphors under X-Ray energy.)

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator in one embodiment of the inventioncontinues by packaging of the combination phosphor-containing device.Specifically, the phosphor-containing drug activator is asepticallypre-weighed and packaged in sterile, nonpyrogenic 10 mL borosilicateamber glass vials. These vials come equipped with a 20 mm crimp neck,fitted with a 20 mm butyl rubber stopper and finally crimp sealed with20 mm flip-top aluminum seals. The final amount of device per sterilecontainer is specified by a kit number.

In one embodiment of the invention, multiple treatment kits can beprepared to accommodate different tumor sizes, with each vial designedfor example to deliver 0.6 mg of phosphors per cubic centimeter of tumorvolume.

Specifics of the container closure system are listed below in , althoughother sterile enclosure systems or enclosure systems that can besterilized are suitable for this invention.

TABLE 8A Container Closure Components Item Description/Name Manufacturer10 mL amber glass vials, 20 Wheaton 20 mm butyl rubber stopper Wheaton20 mm aluminum flip cap Wheaton

All device vials are cleaned and depyrogenated by the manufactureraccording to standardized procedures. After filling the vials with thephosphor-containing drug activator device, vials are stoppered with thebutyl rubber septum top. The stoppered vials are then crimp sealedemploying a flip-off seal and sent for sterilization.

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator in one embodiment of the inventioncontinues by sterilizing the vials. Specifically, crimp sealed vials areautoclaved for 30 minutes (thy-cycle, 250° F. at 14 PSI) and immediatelyremoved from the autoclave. Sterile vials are visually inspected andaffixed with an adhesive label (heat resistant, permanent ink) thatspecifies contents, packaging lot number and date of preparation.Labeled vials are then placed in labeled boxes fitted with individualvial partitions. Sealed cases of devices are labeled with a lot numberand shipped. FIG. 8 is a photographic depiction of on example of final,packaged device kit according to one embodiment of the invention inwhich the device kit includes the novel phosphor-containing devicesdescribed above.

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator in one embodiment of the inventioncontinues by device storage. The sterile materials of the novelphosphor-containing drug activator should be kept at room temperature(20-30° C.) in a humidity controlled environment. Dark storage ispreferred but not required.

As further shown in FIG. 1B, manufacturing of the novelphosphor-containing drug activator continues to steps ensuring qualitycontrol and retention of the characteristics noted above corroborated byanalytical testing before product release. Table 8B below shows alisting of acceptance criteria for the novel phosphor-containing drugactivator prior to the phosphor-containing drug activators being mixedwith a pharmaceutically acceptable carrier and/or UVADEX.

TABLE 8B Acceptance Criteria for the Phosphor-Containing DevicesParameter Method Size SEM Emissions Cathodoluminescence Coating XPSBiocompatibility Chemical extraction and toxicological risk assessmentper ISO 10993-17 Cytotoxicity: 10993-5 Sensitization: 10993-10Irritation: 10993-10 Systemic toxicity: 10993-11 Implantation: 10993-6Pyrogenicity USP 34 <151> Sterility USP <71> Bacterial Endotoxin USP<85>

United States Pharmacopeia (USP) is a compendium of quality controltests for drugs and excipients to be introduced into a medicinalformulation. It is published every year by the United StatesPharmacopoeial Convention.

In one embodiment of the invention, preparation of the vials will beperformed under USP 797 guidelines for compounding sterile preparations.Specifically, using a sterile syringe and 18-20 Ga needle, the novelphosphor-containing drug activator will be hydrated with a specifiedvolume of sterile UVADEX (psoralen). The contents of the vial will bevortexed for a minimum of 3 minutes to ensure proper phosphordispersion, after which the contents of the vial will be transferredinto a standard syringe. The treatment administration syringe will belabeled, at a minimum, with the following information: Subject name,subject number, device name, e1RB #, dose due date and time, pharmacistinitials. Immediately following preparation, the device preparation willbe delivered to the treatment area for administration to the subject.

In one embodiment of the invention, multiple treatment kits can beprepared to accommodate different tumor sizes, with each vial designedto deliver a consistent mass of phosphors per cubic centimeter of tumorvolume. Specifically, five (5) treatment kits can be prepared inaccordance with Table 9 below.

TABLE 9 Kit Packaging- Device Weight Per Kit Tumor UVADEX TotalTreatment Volume (cubic Hydration Final Phosphor (mg/ Group centimeters)Volume (mL) (mg/mL) sterile vial) TG-1 <15 0.75 10 7.5 TG-2   15.1 - 1.510 15.0 TG-3   30.0 - 3 10 30.1 TG-4   50.0 - 4 10 40.1 TG-5 >75 5 1050.2Device Administration and Activation

Administration in one embodiment of the invention is preferably byintratwnoral injection immediately prior to irradiation, at a totalvolume 0.033-0.067 mL per cm³ tumor, including 0.33 to 0.667 mg phosphorper cm³ tumor. In one embodiment of the invention, thephosphor-containing drug activator including the UVADEX will beadministered in multiple injections across the tumor.

In one embodiment of the invention, immediately after injection, thephosphor-containing drug activator will be activated with a low doseX-ray from an on-board imaging (OBI) system of the treatment linearaccelerator. The prescribed dose is 0.6 to 1.0 Gy per fraction.

In one embodiment of the invention, the radiation delivery is set suchthat 1 Gy of radiation is delivered per fraction using 80 kVp X-raysfrom the OBI on the linac CT. In one embodiment of the invention,immediately following intratumoral injection, the region of interestwill be exposed to a low dose kilovoltage radiation, by acquiring a conebeam CT (CBCT). At least one rotational kilovoltage CBCT can be utilizedsuch that images can be stored for future evaluation. Subsequent CBCT scan be shared if there has been a significant reduction in tumor volumesuch that RT re-planning is necessary to avoid overdosing normal tissuesadjacent to the tumor.

In one embodiment of the invention, activation of thephosphor-containing drug activator can be performed using 1.0 Gy of80-100 kVp of x-ray energy delivered from a CT device. Accordingly, thein vivo phosphor-containing drug activator in one embodiment absorbs lowenergy x-rays from commercially available, FDA-cleared CT scanners andre-emits that energy in wavelengths that overlap with the absorptionspectra of UVADEX, an FDA approved drug that promotes apoptosis oftumors cells by for example forming photoadducts with DNA, resulting ininhibition of DNA synthesis and cell division.

Murine Studies

A trial has been conducted for an evaluation of treatment administeredto syngeneic 4T1-HER2 tumors grown on BALB/c mice. There were 4 arms ofthis trial: (1) saline only (control), (2) phosphors alone with x-ray,(3) psoralen (AMT) alone with x-ray, and (4) full treatment includingboth phosphor and psoralen and x-ray irradiation. Treatments were givenin 3 fractions per week, to a total of 6 fractions. In arms 2-3 aconsistent x-ray irradiation technique was used (0.36 Gy delivered at 75kVp by 30 mA in 3 minutes) with 100 μg of phosphor, and 5 μM psoralen(AMT). 0.5 Million 4T1-HER2 cells were injected subcutaneously to theright thigh of each mouse. There were 6-8 mice per arm, and the studywas repeated a second time, yielding effective sample sizes of 12-16.

The results from the in-vivo treatment of BALBC mice with syngeneic4T1-HER2 tumors are shown in FIGS. 9A-9E,

The toxicity of the treatment was evaluated by the monitoring of theaverage body weight for different arms of the treatment, as shown inFIG. 9A. There was no significant loss in body weight for any of thearms. Meanwhile, the data in FIGS. 9B and 9C show the suppression oftumor growth as compared to a saline injection.

In FIG. 9D, the overall saline controls are indicated by line (1). Thetwo other component control arms correspond to 5 μM psoralen (AMT) only,and 100 μg of phosphor only and are shown as lines (2) and (3).respectively. A consistent x-ray irradiation technique was used for allarms (except saline control) which was 0.36 Gy delivered at 75 kVp by 30mA in 3 minutes. (The full treatment, consisting of the device, drug andX-ray, is depicted as x-ray psoralen activated cancer therapy X-PACT,indicated by line (4).)

The first treatment was delivered to the syngeneic 4T1-HER2 tumors, onday 10 after implantation of the 4T1-HER2 tumors. Over the next twoweeks a growth delay was observed in the treatment arm, compared tocontrols. Encouragingly, by day 25, there was a 42% reduction in tumorvolume (p=0.0002). FIG. 9E shows a photographic depiction showing acomparison of the tumors from different mice at different times afterexposure of the mice to different arms of the treatment.

In Vitro Studies

In-vitro studies were conducted on a 4T1 (murine breast cancer) cellsincubated in appropriate growing media and buffers before beingtrypsinized and plated evenly onto twelve (12) well plates for 24 hours.About 20 minutes prior to irradiation, the wells of each plate wereexposed to the following combinations of additives: (1) Control−cellsonly with no additives, (2) UVADEX only, (3) phosphors only, (4)UVADEX+phosphors. Each plate had twelve (12) wells with three wells foreach of the four treatment arms. The plates were then irradiated withx-rays by placing the plate at a known distance from the x-ray source(e.g., 50 cm). After irradiation, the cells were incubated on the platefor 48 hours prior to performing flow cytometry. Guava AnnexinV flowcell cytometry was used to quantify cytotoxicity. The live cells werequantified, and the numbers of cells undergoing early or late apoptosiswere measured. The treatment was then contrasted using a figure of meritreferred to as the fractional cell kill (or the % of cells that were nolonger viable). Table 10 shows this figure of merit for differentratios. The final amount of phosphor used in each case was kept at 50micro-grams. The mixture of phosphors consisting of a 1:2 ratio byweight leads to better fractional cell kill. However, the results showedthe efficacy of the present invention over a wide range of ratios andwhen using only one or the other of the phosphors noted above.

TABLE 10 Fractional Cell Kill with Different Phosphor Ratios NP-200/GTP-Fractional NP-200 GTP-4300 4300 Kill 100%   0% 1:0 4.70% 33% 67% 1:225.10%  0% 100%  0:1 13.30%X-Ray Activation of the Phosphor-Containing Drug Activator

In one embodiment of the invention, the initiation energy that is usedto activate the phosphor device is delivered through a series of x-raypulses consisting of a programmable kV, a set distance from the source,an amperage, and a time. The preferred setting for x-ray pulsing thatactivates UVADEX in the presence of phosphors consists of a distance of50 cm, 80 kV, 200 mA and 800 ms. Each of these pulses is repeated anumber of times to achieve the desired dose. To obtain a dose of 1 Gy,twenty one (21) such pulses are needed. The time between theseprogrammable pulses is optimized at 10 sec. It was found that theprocess is stable and that small variations in any of the settings donot lead to drastic changes in the results.

FIG. 10 is a summary of the fractional cell kill. FIG. 10 illustratesthat the best results were obtained at 80 kV, 800 ms for a fixedamperage of 200 mA.

Methylene blue staining of viable 4T1-HER2 cells confirms that thedevice works well according to the target parameters identified above. Aplate having six (6) wells is subjected to treatment. FIG. 11 is aphotographic depiction showing of Methylene Blue stain for cellviability post treatment with X-ray, phosphors and UVADEX. One well (#1)is the control. One well (#2) has phosphor coated with EC and DLC(H100). One well (#3) has phosphor coated with EC (but no DLC). One well(#4) has drug UVADEX but no phosphors. One well (#5) has drug UVADEX andphosphors coated with EC and DLC. One well (#6) has drug UVADEX. andphosphors coated with EC and no DLC.

All wells were exposed to the optimized x-ray initiation energy notedabove. The combinatory effect of drug plus phosphors is evident andleads to cell death more effectively than the other conditions. The ECcoated phosphors and the EC and DLC coated phosphors both workeffectively. One added benefit to a dual coating is redundancy in safetyof the treatment.

The elapsed time between the various x-ray pulses was considered as avariable. The x-ray pulses were delivered using 5.3 seconds cyclesbetween pulses. These tests were compared to cycles of 10 sec and 20seconds between cycles. FIG. 12 is a plot showing the optimum cycle timebetween pulses. The cycle time that best optimizes the fractional cellkill is 10 sec between pulses. So, in effect, a dose of 1 Gy isdelivered using twenty one (21) X-Ray pulses spaced apart by 10 seconds;and, each x-ray pulse consists of the following settings: 80 kV, 800 ms,200 mA. These were the settings used in the follow on canine in-vivostudies.

Quantification of Cytotoxicity and Apoptosis

Guava Annexin V flow cell cytometry was used to quantify cytotoxicity in3 murine tumor cell lines (mammary -4T1; 4T1-HER2, 4T1 stablytransfected with the human HER2 oncogene; glioma-CT2A; sarcoma KP-B).The mouse breast cancer cell line 4T1 was purchased from ATCC. 4T1-HER2was provided by Dr. Michael Kershaw (Cancer Immunology Program, PeterMacCallum Cancer Centre, Victoria, Australia) and maintained in DMEMwith penicillin/streptomycin and 10% FBS The Sarcoma KP-B cell lineswere derived from primary tumors LSL-Kral; p53 Flox/Flox mice (45).

Tumors between 250 and 300 cm³ were digested using a mixture ofcollagenase/dispase/trypsin for 1 hour, passed through a 70-micronfilter, and cultured 5 to 8 passages before being used for experiments.Cells were cultured in DMEM medium supplemented with 10% FBS andincubated at 37° C. with 5% CO₂ in a humidified cell-culture incubator.

In-vitro studies were conducted on plated cells following standardprocedures. Cells were maintained in RPMI-1640 supplemented with 10%fetal bovine serum and L-glutamine from GIBCO (Grand Island, N.Y.)growing in a humidified atmosphere of 5% CO₂. After incubation, cellswere trypsinized and plated evenly onto twelve 12-well plates for 24hours. About 20 minutes prior to irradiation, the 12 wells of each platewere exposed to the following combinations of additives: (1)control−cells only with no additives, (2) UVADEX only, (3) phosphorsonly, (4) UVADEX+phosphors. Each plate had 12 wells with three wells foreach of the four treatment arms. The plates were then irradiated withx-rays by placing the plate at a known distance from the x-ray source(50 cm). After irradiation, the cells were incubated on the plate for 48hours prior to performing flow cytometry. For compatibility with 96-wellGuava Nexin® assay, the remaining cells were again trypsinized. (afterthe 48 hour incubation) and plated onto the 96-well plate,

A range of x-ray activation protocols were investigated to determine thecytotoxic efficacy in relation to x-ray energy (kVp), total dose, anddose-rate. kV beam energies ranging between 80-100 kVp wereinvestigated. kV beams were obtained from various x-ray generatingequipment, including orthovoltage units, standard diagnosticradiographic, fluoroscopic, and cone-beam computed tomography (CBCT)systems. The primary kV x-ray source utilized in the in vitro studies(for all data presented, unless stated otherwise in the figure caption)was a Varian on-board-imaging x-ray source commonly found on Varianmedical linear accelerators. The x-ray dose delivered for the in-vitroirradiations studied here ranged from 0.2-2 Gy, with main emphasis onlower doses of 0.5-1 Gy.

For x-ray irradiation, the well plates were positioned at a set distance(typically 50 cm) from the x-ray source on a solid water phantom and theposition of the well plates within the x-ray beam was verified by lowdose kV imaging. Irradiations were typically delivered in a “radiograph”mode; where multiple pulses of a set mA (typically 200) and ms(typically 800) and pulses were delivered every 5-15 seconds. Inexperiments investigating dose-rate effects, the radiation was alsodelivered in a “pulsed fluoroscopy mode” (10 Hz) at the maximum mAsetting. The most common kVp settings were 80 and 100 kVp with no addedfiltration in the beam (Half Value Layer=3.0 and 3.7 mm Al,respectively).

Two primary flow cytometry analyses were used, both determined at 48hours after treatment. Cells plated in 12-well plates, where individualwells in each plate received different experimental conditions (e.g.,psoralen concentration), but the same x-ray dose all wells in a givenplate receive the same x-ray dose). The first analysis evaluated wasmetabolic cell viability (herein referred to as cell viability)calculated from the number of whole cells per well as determined usingforward scattering (ESC). For each well, cell viability was normalizedto that in a control well without psoralen or phosphors but which didreceive radiation. (All wells on a given plate receive the same dose.)The second assay is Annexin V positivity, which is the fraction ofviable cells that are Annexin V+ by flow cell cytometry. The Annexin V(+) signal was corrected by subtracting the control signal from theno-psoralen/phosphor well on the same plate.

Other assays were used to provide independent complimentary informationon cell viability, e.g. Methylene blue staining and ATP-inducedLuminescence imaging (Cell-Titer-Glo® Luminescence Cell ViabilityAssay). The luminescence imaging permitted investigation of thecytotoxicity of psoralen activated directly with a UV lamp, and in theabsence of phosphors and x-ray radiation.

Several statistical analyses were completed, including unequal variancetwo-sample t-tests, Analysis of Variance (ANOVA), and multi-variableregression. The unequal variance two-sample t-test tests the nullhypothesis that the means of observations (e.g. viable cells, Annexinsignal) in two different populations are equal. The p-value gives theprobability that the observed difference occurred by chance.Multi-variable regression was used to test the null hypothesis thatpsoralen and phosphor had no effect on Annexin V (+) signal and to testif there is a first-order interaction between the two therapeuticelements. Non-parametric statistical analysis were also performed foreach test, and showed consistent results.

Results of statistical analyses are classified in four categories:weakly significant, moderately significant, significant, and verysignificant. A single asterisk indicates weakly significant statistics(*), where the p-value is in the range 0.01<p<0.05. Double asterisksindicate moderately significant statistics (**), where 0,001<p<0.01.Triple asterisks indicate significant statistics (***), where0,0001<p<0.001. Quadruple asterisks indicate very significant statistics(****), where p<0.0001. This convention will be used throughout theResults and Discussion section.

FIGS. 13A-13D illustrates the efficacy of treatment in-vitro in 4T1-HER2cells, utilizing a regimen of 1/10-diluted UVADEX (with equivalent of 10uM 8-MOP), 50 μg/mL phosphor 1 Gy of 80 kVp x-rays. FIG. 13A presentsthe cell viability data for three treatment conditions: UVADEX alone,phosphors alone, and the combination of UVADEX and phosphors. These datawere compiled from experiments performed on 5 different days (within 1month), including 15 separate experimental and 10 control plateirradiations. FIG. 13B presents the Annexin V (+) signal for the same 3conditions as FIG. 13A. FIGS. 13C and 13D show corresponding images ofviable cell populations revealed by methylene blue staining. Two resultsfrom two separate plates are shown, each with identical preparations toinvestigate reproducibility. Three concentrations of phosphor (25, 50, &100 μg/mL) were tested with the UVADEX concentration fixed at 1/10dilution (10 uM 8-MOP). The anti-tumor effect is evident from this data.In FIGS. 13A-13D, the anti-tumor effects of the treatment and itsindividual components on 4T1-HER2 cells. In FIG. 13A, cell viabilityafter treatment (10 μM 8-MOP equivalent dilution of UVADEX, 50 μg/mLphosphor, 1 Gy of 80 kVp radiation) as determined by Guava flow cytomecytometry is depicted. N is the number of independent measurements(different days), and error bars indicate one standard deviation. InFIG. 13B, the Annexin V (+) fraction of viable cells shown in 13A. InFIGS. 13C and 13D, cell viability illustrated by methyl blue stainingfor identical plates each receiving 1 Gy of 80 kVp x-rays is depicted.Each plate contained wells including no additives (control), threeconcentrations of phosphor only (25, 50, & 100 μg/mL. with DLC), UVADEXonly (10 uM 8-MOP equivalent dilution), and three combination treatmentregimes

The relative effectiveness of UV activated psoralen on the threeindependent cell lines noted above is shown in FIGS. 14A and 14B. FIG.14A shows comparable sensitivity of CT2A (murine malignant glioma), 4T1and KP-B (sarcoma) cell lines to psoralen activated by the phosphordevice. FIG. 14B presents data on CT2A malignant glioma cells, for arange of treatment parameters including variable x-ray dose (0, 0.67 and1 Gy). phosphor concentration (50 or 100 μg) and psoralen concentration(8-MOP) at 10, 20 and 40 μM respectively. For FIG. 14A, x-ray induced UVlight activated psoralen was observed to reduce viable cells in 3 celllines (data from Cell-Titer-Glo® Luminescence Cell Viability Assay underx-ray induced UV light). N=4 for each cell line at each UV lightcondition (0, 0.25, 0.5, 1.0 J/cm2). The psoralen concentration was 40μM. For FIG. 14B, in CT2A cells, the treatment cytotoxicity increaseswith X-ray dose (0, 0.67 and 1.00 Gy respectively), concentration of8-MOP psoralen (10, 20 and 40 μM respectively), and phosphor (50 and 100μg/ml) respectively (p values shown thereon).

FIG. 15A presents a multi-variable linear regression analysis onthirty-six (36) independent measurements (wells) of Annexin V (±) as afunction of two variables: psoralen concentration, and phosphorconcentration. Psoralen and phosphor concentrations ranged front 10 μMto 50 μM and 25 μg/mL to 200 μg/mL, respectively. Each of the 36 wellswas irradiated with 1 Gy of x-ray radiation at 80 kVp. The fit had thefollowing form given in Equation 1 (where P=phosphor, andConc=concentration):Annexin V(+)=A+B*[8-MOP Conc]+C*[P Conc]+D*[8-MOP Conc.]*[P Conc.]  Eq 1

For FIG. 15A, a multi-variable linear regression analysis on thirty-six(36) independent measurements of Annexin V (+) in 4T1-Her2 cells as afunction of psoralen and phosphor concentration. All samples received anx-ray dose of 1 Gy at 80 kVp. Psoralen and phosphor concentrationsranged from 10 μM to 50 μM and from 25 μg to 200 mg respectively. Thefilling equation is given at the top of the Table and in Equation 1. Theoverall fit was statistically significant as were each of the fitcoefficients. FIG. 15B shows a subset of data collected whichdemonstrate the magnitudes and effects of increasing concentrations ofpsoralen and phosphor on Annexin V (+) staining. For FIG. 15B, a subsetof the data that was collected on a single day, indicating magnitude andtrends. Neat UVADEX 8-MOP) was diluted to 10, 20. and 50 μM, or 1:10,1:5, and 1:2 UVADEX. Four repeats (N=4) were performed for the conditionwith 50 μg/mL of phosphor and 10 μM of 8-MOP diluted from UVADEX.

FIG. 16 compares the use of the phosphor-containing drug activator attwo different x-ray energies (80 and 100 kVp). These experimentsinvolved 4T1-HER2 cells treated with 10 μM 8-MOP equivalent UVADEX, and50 μg/mL phosphors. Specifically, in FIG. 16, a treatment effect in4T1-her2 was observed at both 80 and 100 kVp, with suggestion that 80kVp may be slightly more effective than 100 kVp (p=0.011, *). This dataacquired from X-PACT treatment of 4T1-HER2 cells with constant phosphorconcentration of 50 μg/mL and UVADEX diluted to 8-MOP concentration of10 μM (1:10 dilution). N is the number of independent measurements.

Discussion of Murine Studies

In the 4T1 in-vitro cell viability analysis (FIG. 13A), a substantialreduction in viable cells (˜48%, p<0001) was observed in the fulltreatment condition (phosphor device. psoralen, and x-ray). Cellviability was higher (70-85%) in the control conditions.

The effect of adding radiation to the control conditions did not lead toa reduction in cell viability. The addition of radiation to UVADEX alone(left bars in FIG. 13A) had no significant effect on cell viability(p=0.97). Cells exposed to phosphors alone (middle bars in FIG. 13A)show a slight reduction in cell viability (˜8%, p=0.034) when radiationwas added. The increased toxicity associated with the presence of bothphosphors and x-rays could be attributed to DNA damage arising by UVlight from x-ray induced phosphorescence from the phosphors. Substantialcytotoxicity (˜80%) was only observed in the full treatment arm,demonstrating the synergistic therapeutic effect of the combination ofphosphor, UVADEX and radiation.

In the 4T1 in-vitro apoptotic analysis (FIG. 13B), cells exposed toUVADEX alone (left bars) exhibited negligible apoptotic activity eitherwith or without x-ray (p values of 0.90 and 0.09 respectively). Therewas a slight increase in Annexin V staining when cells were exposed tophosphor alone (middle bars) (˜1%, p=0.098) suggesting a slight toxicityof the phosphors. However, it was only when both phosphor and UVADEXwere combined (right bars) that a statistically significant increase inAnnexin V staining was observed (˜8%, p<0.0001), indicating an increasein apoptosis. The anti-tumor effects of the treatment were furtherillustrated in the methyl blue staining in FIGS. 13C and 13D. In bothtreatments, little effect was observed for the individual components ofUVADEX and phosphor. The methyl blue staining results are consistentwith the flow cytometry data, in that all treatment components arerequired for high cytotoxicity. Less cytotoxicity is manifest in thefirst treatment condition because of decreased phosphor concentration.

When evaluated on the three different cell lines (FIG. 14A), an ANOVAanalyses reveals no statistically significant differences in thesensitivity of these lines either to individual components or to fulltreatment (p>0.05). This observation suggests that treatment may haveapplicability to a range of different tumor types. In CT2A malignantglioma cells, cell cytotoxicity was observed (FIG. 14B) to increase withthe magnitude of X-ray dose (0, 0.66 and 1 Gy respectively),concentration of 8-MOP psoralen (10, 20 and 40 μM respectively), andphosphor (50 and 100 μg/ml respectively). Two-sample unequal variancet-test analyses revealed that the effect of 1 Gy radiation wassignificant on CT2A cells for 20 μM 8-MOP+50 μg/mL phosphors and largerconcentrations, but was not significant below those concentrations,especially for the control group. This suggests that radiation itself isnot the cause of the increased cytotoxicity.

The most comprehensive in-vitro 4T1 analysis (FIG. 15A) revealed astatistically significant multi-variable linear regression (R2=0.72),The synergy interaction coefficient D was statistically significant(p<0.0001) and positive indicating an enhanced effect when phosphor andpsoralen were present. The interaction coefficients for psoralen andphosphor alone were only weakly suggestive (p˜0.1 and 0.05respectively). The p values indicate likely significance, hut gave noindication of magnitude of effect, which is shown in FIG. 15B. A generalobservation from this data, acquired with constant x-ray dose, is thatapoptotic fraction induced by the treatment increases with eitherincreasing phosphor or psoralen concentration.

In FIG. 16, the in-vitro study investigated whether changing x-rayenergy had much effect on the treatment efficacy. This study indicatedthat ˜80 kVp would be optimal, but a higher energy would have anadvantage from treatment delivery perspective (greater penetration intissue). For this reason a 100 kVp beam energy was investigated. Anincrease in apoptotic signal (over the control) was observed fortreatments at both energies.

Canine Study

A pilot study of spontaneous tumors in canine companion animals wasconducted. The primary endpoint was device safety, with secondaryendpoints to include treatment feasibility and tumor response. Each ofsix dogs was treated three times a week for three consecutive weeks. Thetreatment consisted of anesthetizing the dog, administering thephosphor-containing drug activator in a slurry of UVADEX and delivering0.6 to 1 Gy of 80 kVp x-ray energy from a cone beam CT system. Dogs werefollowed for one year post treatment.

The following protocols were utilized in the canine study.

Protocol Summary: Without limiting the invention, the followingdescribes nine (9) repeated sessions including tumor measurements,visualizations, and treatments. (More or less than nine sessions can beused depending on the state of the malignancy. Indeed, a treatment with3-5 sessions might be useful in situations where the tumor is nearsurface and thorough exposure of the tumor is likely at each session.Alternatively, a treatment with 12-15 sessions might useful insituations where the tumor is within a human organ inside themusculoskeletal system exposure of the tumor is limited to the radiationexposure dose. Moreover, while described below with emphasis on caninetreatments, the invention is not limited to the use of these protocolsto canines as other animal and human patients could benefit.)

While other measurements, evaluations, and treatments for themalignancies can occur, each session typically included: tumormeasurements, toxicity scoring, labwork (collected-at treatments #2, 3,6 and 9), intraturnoral injections of drug and energy modulatorsubstances (preferably while anesthetized), and radiation treatment (RT)with for example radiation of 1 Gy via 80 kVp X-rays. Following the ninesessions, there were follow-up weekly evaluations 3 and 6 weeks aftercompleting the last RT. The follow-up weekly evaluations a) evaluatedacute local and systemic toxicity via physical examination and routinelabwork, and b) estimated the tumor volume. Following the nine sessions,there were follow-up monthly evaluations at 3, 6, 9 and 12 months aftercompleting the last RT. The follow-up monthly evaluations a) evaluateddelayed local toxicity via physical examination, and b) describedduration of local tumor in enrolled cases.

Treatment and Imaging: As noted above, subjects in the protocol wereanesthetized nine (9) times over 3 weeks. The treatment includedintratumoral injections of a slurry containing the novelphosphor-containing drug activator described above. During the radiationtreatment, the tumor is imaged preferably using a cone-beam CTtechnology. The imaging may provide an indication of the localization ofphosphors and there distribution throughout the volume of the tumor.

Intratumoral Injections:

1. 3-dimensional caliper measurements of the tumor.

2. Tumor volume will be estimated by multiplying the product of 3orthogonal diameters by π/6.

3. The total volume to be injected into each tumor follows the regimentoutlined below using vials of sterilized phosphor to be mixed UVADEX™(100 μg/mL 8-MOP) as the sole diluent

TABLE 11 mL of slurry per milligrams of phosphor per Total Tumor cm³tumor cm³ of tumor volume volume Min Max Min Max injected 8-15 cubic0.034 0.063 0.333 0.625 0.5 mL centimeters 15-29.9 cubic 0.033 0.0670.334 0.667 1 mL centimeters 30-49.9 cubic 0.040 0.067 0.401 0.67 2 mLcentimeters 50-74.9 cubic 0.040 0.060 0.401 0.600 3 mL centimeters75-99.9 cubic 0.040 0.053 0.400 0.533 4 mL centimeters >100 cubic 0.0440.050 0.435 0.500 5 mL centimeters

Especially for the canine treatments, but also for other patients, thefur/hair was clipped to improve visibility of the tumor. The tumor skinoverlying the tumor was prepared via three (3) alternating scrubs ofalcohol (or sterile saline) and chlorohexidine (or iodine).

A grid (e.g., of 1 cm squares) can optionally be used to ensuredistribution of the phosphor injections over the course of multipletreatments. Each week, typically, the center and corners can be marked(e.g., with a permanent or paint marker) in blue at the first of thatweek's treatments, green at the second treatment and white at the 3rdtreatment The grid can serve as a template for free-hand injection ofthe psoralen/phosphor slurry. The grid can be rotated (in the sameplane, pivoting about the center) 0.25 cm per day.

An appropriate amount of individual, coated phosphors were weighed intoa glass crimp top vial, fitted with a Teflon septum top and an aluminumcrimp ring, sealed via a crimp tool and autoclaved on a dry goods cycle(250° C., 30 minutes) and immediately removed from the autoclave,allowing to cool to room temperature. The sterilized materials werestored at room temperature, protected from light until use.

In one example, approximately 30 minutes prior to injection, sterilizedphosphors in sealed, crimp top vials were rehydrated with the indicatedvolume of UVADEX via a sterile needle through a septum cap. Postaddition of UVADEX, the entire mixture was continuously vortexed (usinga laboratory grade vortex mixer set to the highest setting) forapproximately 2 minutes. The mixed sample was introduced into a sterilesyringe and sealed with a luer lok cap. Syringes were delivered to thetreatment room and immediately prior to intratumoral injection, thesealed syringed was mixed via vortex for approximately 30 sec followedby injection into the desired subject site.

A 20-25 gauge sterile hypodermic needle was used to make free-handinjections in multiple injection sites across the tumor, or at thecorner of each square on the grid (if used). (Changing the size of theneedle or syringe can be used to optimize the injection distribution.)The total volume to be injected was divided evenly. Injections werepreferably made into palpable tumor, but not adjacent normal tissues.The plunger was depressed as the needle was withdrawn from the tumor, tomaximize the distribution of phosphors and UVADEX.

In one embodiment, tumors on or near the surface can be palpated tofacilitate delivery of the phosphors. Typically, multiple injections aremade to help distribute the phosphors throughout the tumor mass. Fordeeper treatment areas where the tumor cannot be palpated, ultrasoundguidance can be employed. Additionally, ultrasound can be used to assistin the dispersion of the UVADEX after the phosphors were delivered tothe treatment site.

This protocol used UVADEX (8-methoxypsoralen) as the activatablepharmaceutical agent (using concentrations in the range of 10 μg/mL to50 μg/ml), and used H100 (diamond coating formed in the presence of 40atomic % hydrogen) and EC (ethyl cellulose coating) with the combinationphosphor being a 1:2 mixture of NP200:GTP-4300.

Following injection of the phosphors and UVADEX, radiation therapyfollowed immediately.

Radiation Therapy:

0.6-1 Gy of radiation was delivered per treatment session using 80-100kVp X-rays from the on board imaging (OBI) device of a Novalis Txradiosurgery platform. (Besides the OBI device of a Varian linearaccelerator, a Trilogy, iX, TruBeam, etc. could be used with appropriateadjustment of x-ray dose and energy). With regard to the Novalis Txplatform, this platform includes three imaging modalities forpinpointing a tumor and positioning the patient with high precision. TheOBI may be programmed to provide continual imaging during treatment todetect movement and support robotic adjustments in patient positioningin six dimensions (although image quality during treatment will not beoptimum). The patient disposed on the Novalis Tx platform is positionedabove the concentric imaging position of the x-ray source at a distanceof 50 to 70 cm from the x-ray anode.

Subjects can be positioned on a linear accelerator's treatment couch(with the gantry at zero degrees) with the tumor centered at theisocenter of the linear accelerator (centering accomplished using visualinspection and lasers from the linear accelerator); the subject can thenbe vertically raised to a position with a source to surface distance SSDof 70-90 cm, per the optical distance indicator. This corresponds to asource to surface distance of 50-70 cm when the kilovoltage X-ray source(in the on-board imaging system) is moved to zero degrees forirradiation. Subjects with small body size are elevated on a riser whichsits atop the 1 linear accelerator's couch, to facilitate a terminal SSDof 50-70 cm; the goal is always to make the terminal SSD (from the kVsource) as close to 50 cm as possible, to minimize treatment times.

Immediately following the final intratwnoral injection of the phosphordevice (preferably within several minutes) alignment radiation from thex-ray source (fluoroscopy and/or planar radiographs) confirmed that thesource was properly positioned to deliver x-rays to the tumor site byimaging of fiducial markers around the tumor. Then, within several or 5minutes of the final injection, x-rays from the 80 kVp source pulsingfor 800 microsecond pulses was delivered to the target site. In oneexample, the flux of x-rays was interrupted periodically and restarteduntil a dose of 0.5 to 1.0 Gy has been delivered in total. As anexample, multiple pulses can be used with each pulse is set for 80 kV,200 mA, 800 milliseconds. The total dose (in Gy) delivered wasdetermined by the number of pulses delivered. The number of pulsesdelivered to achieve the therapeutic dose was a function of the depthand location of the tumor. Bone mass in the exposure region should beaccounted for. For example, a radiation therapy typically was designedfor a maximum estimated fractional bone dose of 3 Gy per fraction.

After, this therapeutic radiation treatment (preferably less than 30minutes, more preferably less than 20 minutes), the region of interestwas typically exposed to the kilovoltage radiation using the VarianNovalis OBI (on bard imaging system). At least one rotationalkilovoltage CBCT is typically scheduled such that images can be storedfor evaluation, Additional beam angles collimated per therecommendations can be used.

Sample Collection

Blood samples are collected via peripheral venipuncture, or from asampling catheter. Free-catch urine samples are collected forurinalyses.

TABLE 12 Number of Volume per samples Time of sample Assay Fluid sample(per dog) collection Complete blood Whole blood 1 mL 7 Baseline, day 3,count (in EDTA) week 1, 2, 3, 6 and 9 Chemistry profile Serum 1 mL 7Baseline, day 3, week 1, 2, 3, 6 and 9 Urinalysis Urine 1 mL 7 Baseline,day 3, week 1, 2, 3, 6 and 9 PK -Day 1 Plasma 0.5 mL 8 Baseline, 10, 30(psoralen) minutes, 1, 1.5, 3, 6 and 12 hours PK -Day 9 Plasma O.5 mL 4Baseline, 30 (psoralen) minutes, 1.5 and 6 hours Elemental Plasma O.5 mL10 Baseline, 30 analysis minutes, 1.5 hours, (phosphor) 6 hours, 12hours, 3 days, 1, 3, 6 and 9 weeks Stored sample (for Plasma O.5 mL 10Baseline, 30 future analyses of minutes, 1.5 hours, immune and/or 6hours, 12 hours, inflammatory 3 days, 1, 3, 6 and mediators) 9 weeks

Pharmacokinetic samples were frozen and stored. The pharmacokineticstudy determined whether enough psoralen is absorbed systemically tocreate a concern regarding systemic exposure and toxicity.

Blood and urine samples for elemental analysis were frozen and stored.Additional plasma samples are collected and stored.

The preceding treatment in one patient was further supplemented with a“booster” treatment, that is, the initial treatment considered a“priming treatment, with an additional treatment used to “boost” theinitial treatment response. A “booster treatment” in one embodimentcould involve re-injecting the tumor with psoralen (or otherphotoactivatable drug) and radiating the tumor site again. A “boostertreatment” in another embodiment could involve re-injecting the tumorwith psoralen (or other photoactivatable drug) and an energy modulationagent and radiating the tumor site again. A “booster treatment” inanother embodiment could involve radiating the tumor site again, but ata radiation level considered to be at either a palliative or therapeuticlevel. The purpose of these “booster” treatments is to activate theimmune response initially or originally generated within the patientduring the initial treatments.

In one embodiment of the booster treatment, the phosphor concentrationwas increased to 20 mg/mL, the amount of UVADEX was increased 2-4 times,and the treatment frequency was increased to five (5) treatments in five(5) consecutive days. Furthermore, the timing between the prime (initialtreatment sessions such as the nine treatments described above) and thebooster treatment was set to allow for an initial humoral or cellularimmune response, followed by a period of homeostasis, most typicallyweeks or months after the initial priming treatment.

Clinical Analysis

Hematology Summary Results

Analyzed using Siemens Advia 120:

The results of the clinical tests showed that the minimum mean cellhemoglobin concentration (MCHC) was statistically significantly lessthan baseline. Despite statistical significance, all values remainwithin the reference range, and are of no appreciable clinicalsignificance. The minimum lymphocyte count is statisticallysignificantly less than baseline. The 95% confidence interval of thatminimum lymphocyte count is below the lower limit of the referencerange. The cause of this post-treatment lymphopenia is not known, nor isit of clinical significance.

Urinalysis Summary Results

There were no statistically significant perturbations in parametersmeasured via urinalysis. Of note:

-   -   2/6 dogs developed significant but transiently increased        proteinuria (4+ bumin) post-treatment    -   4/6 dogs were noted to have 0-5 fine granular casts after        treatment; these persisted at the 6 week follow-up exam in one        dog    -   4/6 dogs were noted to have 0-2 hyaline casts after treatment;        these persisted at the 6 week follow-up exam in one dog    -   2/6 dogs were noted to have rare bilirubin crystals after        treatment; none persisted beyond the 3 week recheck visit    -   4/6 dogs were noted to have rare to moderate triple phosphate        crystals; these persisted at the 6 week follow-up visit in 2/6        dogs        Normal Tissue Toxicity Summary Results

One dog experienced grade I skin toxicity (hyperpigmentation andalopecia); first noted at 3 week recheck; has not resolved.

One dog experienced grade I oral mucosal toxicity (erythema); firstnoted at 3 month recheck; has not been re-evaluated since then.

Tumor Response Summary Results

-   -   Tumor response was evaluated in accordance with the Response        Evaluation Criteria In Solid Tumors (RECIST) criteria, below:    -   Complete response (disappearance of target lesion)    -   Partial response (at least 30% decrease in longest measured        dimension, compared with baseline)    -   Stable disease (neither CR, PR nor PD)    -   Progressive disease (at least 20% increase in any measured        dimension, compared with baseline and most recent measurement)

TABLE 13 Tumor response by RECIST. Subject Response #1 Partial Responseat 3 weeks, Complete Response at 6 weeks, 3 months, 6 months, 9 monthsand 12 months #2 Stable Disease at 3 weeks, 6 weeks and 3 months.Pursued booster treatment - now a strong Partial Responder 8 months postbooster treatment #3 Stable Disease at 3 weeks, Progressive Disease at 6weeks, dismissed from study at 3 months and given booster treatment.Elected for surgical removal of tumor #4 Stable Disease at 3 weeks, 6weeks, 3 months, progression at 6 months, dismissed from the study topursue other treatments. #5 Stable Disease at 3 weeks, 6 weeks, and 3months. Progressive Disease at 6 months, dismissed from the study topursue booster. Elected surgical removal of the tumor. #6 Stable Diseaseat 3 weeks, progressive disease at 6 weeks, dismissed from study at 3months

FIGS. 17A and 17B demonstrate a dramatic and complete response in onesubject. The depicted pretreatment photograph (FIG. 17A) is directed toa rostral maxillary tumor with a histopathologic diagnosis of a roundcell tumor. The post treatment photograph (FIG. 17B) was taken threeweeks after the completion of treatment. This dog remains in completeresponse one year after treatment.

FIGS. 18A (pre-treatment) and 18B (post-treatment) depict anotherdramatic treatment effect. This subject had a maxillary plasma celltumor with disease progression after melphalan chemotherapy, This dogwas treated with the phosphor-containing drug activator and 8-MOP andhad stable disease thereafter. An additional “booster” treatment(consisting of 5 treatments in 5 consecutive days) was added, afterwhich the intra-oral part of the tumor completely resolved. Theinfra-oral component has remained stable for several months.

Variations

In another embodiment, particularly for more aggressive cancers, anintervening treatment between the prime and boost stages can be providedto stunt the growth of the tumor while the immune system develops aresponse. The intervening treatment can take the form of palliativeradiation, or other treatments known to those skilled in the art.

The invention can utilize one or more booster treatments in a mannersimilar to that described by David L. Woodland in their paper in TRENDSin Immunology Vol. 25 No. 2 February 2004, entitled “Jump-Starting theImmune System: Prime-Boosting Comes of Age” (the entire contents ofwhich are incorporated herein by reference). The basic prime-booststrategy involves priming the immune system to a target antigen, or aplurality of antigens created by the drug and/or radiation induced cellkill, and then selectively boosting this immunity by re-exposing theantigen or plurality of antigens in the boost treatment. One keystrength of this strategy in the present invention is that greaterlevels of immunity are established by heterologous prime-boost than canbe attained by a single vaccine administration or homologous booststrategies. For example, the initial priming events elicited by a firstexposure to an antigen or a plurality of antigens appear to be imprintedon the immune system. This phenomenon is particularly strong in cellsand is exploited in prime-boost strategies to selectively increase thenumbers of memory T cells specific for a shared antigen in the prime andboost vaccines. As described in the literature, these increased numbersof T cells ‘push’ the cellular immune response over certain thresholdsthat are required to fight specific pathogens or cells containing tumorspecific antigens. Furthermore, the general avidity of the boostedT-cell response is enhanced, which presumably increases the efficacy ofthe treatment.

Here, in this invention and without limitation as to the details butrather for the purpose of explanation, the initial treatment protocoldevelops antibodies or cellular immune responses to thepsoralen-modified or X-ray modified cancer cells. These “initial”responses can then be stimulated by the occurrence of a large number ofnewly created psoralen-modified or X-ray modified cancer cells, As such,the patient's immune system would mount a more robust response againstthe cancer than would be realized in a single treatment series.

In one embodiment of the invention, as noted above, the treatments forthe non-adherent or liquid tumors can be given once, or periodically(such as 3 to 5 times a week), or intermittently, such as 3 to 5 times aweek, followed by a period of no treatment, typically one to two weeks,followed by another treatment period of 3 to 5 times a week.

Additionally, a prime-boost strategy can be employed, such as isdescribed herein for the treatment of solid tumors. The prime phase canbe a single treatment, periodic treatment or intermittent treatment,followed by a period of no treatment, typically 6-12 weeks, followed bya booster treatment. The booster treatment can be the same duration andfrequency as the prime treatment, or can be accelerated or shortened.

In one embodiment of the invention, prior to the initial treatment orprior to booster treatments, the immune system of the subject could befurther stimulated by injection of a more conventional vaccine such asfor example a tetanus vaccine. Prior work by others has shown theefficacy of a tetanus booster to bolster the immune system's attack onthe tumor by helping cancer vaccines present in the subject migrate tothe lymph nodes, activating an immune response. Here, in this invention,the autovaccines generated internally from the treatments describedabove could also benefit from this effect.

The invention also has utility in treating non-adherent (liquid) tumors,such as lymphoma. Instead of injecting the phosphors and drug into thesolid tumor, the phosphor and drug combination can be injected into alymph node, preferably the draining lymph node distal to a lymphomatumor, or any lymph node with disease involvement. Alternatively,treating any area with a lymphoma infiltration is acceptable.

Debris from dead and dying tumor cells would be transported to regionallymph nodes where immune activation would occur and tumor specificimmune cells would then recirculate and begin to destroy tumor cells atmultiple sites. This killing of tumor cells in the lymph or any organwith a lymphoma infiltrate creates more immune stimuli for activation inthe regional lymph nodes and further re-circulation, making repeattreatments beneficial.

In one embodiment of the invention, intervening treatments to controlthe growth or spread of the lymphoma while the immune system activatescan also be added. These treatments can include palliative x-ray, enzymetreatments such as asparginase, chemotherapy, or surgery.

The typical tube voltage for radiography is typically in the range of60-120 kV. The x-ray beam is then passed through filtration achieved byinterposing various metal filters in the x-ray path. The metals that canbe used include Aluminum (Al) and Copper (Cu). The filtration of thebeam eliminates noise and results in a cleaner output beam,preferentially removing softer photons. This leads to a cleaner spectrumand systems from different vendors would result in having substantiallythe same output spectrum. After filtration the beam is passed through acollimator. X-ray radiation can be collimated into a fan-shaped beam.The beam is passed through an adjustable aperture. Lead (Pb) plates ofabout 2 mm in thickness can be used to block the beam and limit theexposure of x-ray to the tumor area.

The 60-120 kV beam can be sufficient to activate the bio-therapeuticagent via the phosphors described in this invention.

In one embodiment, a method in accordance with the present inventionutilizes the principle of energy transfer to and among different agentsto control delivery and activation of cellular changes by irradiationsuch that delivery of the desired effect is more intensified, precise,and effective than the conventional techniques. The phosphors notedabove represent but one energy modulation agent of the presentinvention. In general, at least one energy modulation agent can beadministered to the subject which adsorbs, intensifies or modifies saidinitiation energy into an energy that effects a predetermined cellularchange in said target structure. The energy modulation agent may belocated around, on, or in said target structure. Further, the energymodulation agent can transform a photonic initiation energy into aphotonic energy that effects a predetermined change in said targetstructure. In one embodiment, the energy modulation agent decreases thewavelength of the photonic initiation energy (down convert). In anotherembodiment, the energy modulation agent can increase the wavelength ofthe photonic initiation energy (up convert). In a different embodimentthe modulation agent is one or more members selected from abiocompatible fluorescing metal nanoparticle, fluorescing metal oxidenanoparticle, fluorescing dye molecule, gold nanoparticle, silvernanoparticle, gold-coated silver nanoparticle, a water soluble quantumdot encapsulated by polyamidoamine dendrimers, a luciferase, abiocompatible phosphorescent molecule, a combined electromagnetic energyharvester molecule, and a lanthanide chelate exhibiting intenseluminescence.

In one aspect of the invention, a downconverting energy modulation agentcan comprise inorganic particulates selected from the group consistingof: metal oxides; metal sulfides; doped metal oxides; and mixed metalchalcogenides. In one aspect of the invention, the downconvertingmaterial can comprise at least one of Y₂O₃, Y₂O₂S, NaYF₄, NaYbF₄, YAG,YAP, Nd₂O₃, LaF₃, LaCl₃, La₂O₃, TiO₂, LuPO₄, YVO₄, YbF₃, YF₃, Na-dopedYbF₃, ZnS; ZnSe; MgS; CaS and alkali lead silicate includingcompositions of SiO₂, B₂O₃, Na₂O, K₂O, PbO, MgO, or Ag, and combinationsor alloys or layers thereof. In one aspect of the invention, thedownconverting material can include a dopant including at least one ofEr, Eu, Yb, Tm, Nd, Mn Tb, Ce, Y, U, Pr, La, Gd and other rare-earthspecies or a combination thereof. The dopant can be included at aconcentration of 0.01%-50% by mol concentration.

In one aspect of the invention, the downconverting energy modulationagent can comprise materials such as ZnSeS:Cu, Ag, Ce, Tb; CaS: Ce,Sm;La₂O₂S:Tb; Y₂O₂S:Tb; Gd₂O₂S:Pr, Ce, F; LaPO₄. In other aspects of theinvention, the downconverting material can comprise phosphors such asZnS:Ag and ZnS:Cu, Pb. In other aspects of the invention, thedownconverting material can be alloys of the ZnSeS family doped withother metals. For example, suitable materials include ZnSe_(x)S_(y):Cu,Ag, Ce, Tb, where the following x, y values and intermediate values areacceptable: x:y; respectively 0:1; 0.1:0.9; 0.2:0.8; 0.3:0.7; 0.4:0.6;0.5:0.5; 0.6:0.4; 0.7:0.3; 0.8:0.2; 0.9:0.1; and 1.0:0.0.

In other aspects of the invention, the downconverting energy modulationagent can be materials such as sodium yttrium fluoride (NaYF₄),lanthanum fluoride (LaF₃), lanthanum oxysulfide (La₂O₂S), yttriumoxysulfide (Y₂O₂S), yttrium fluoride (YF₃), yttrium gallate, yttriumaluminum garnet (YAG), gadolinium fluoride (GdF₃), barium yttriumfluoride (BaYF₅, BaY₂F₈), gadolinium oxysulfide (Gd₂O₂S), calciumtungstate (CaWO₄), yttrium oxide:terbium (Yt₂O₃Tb), gadoliniumoxysulphide:europium (Gd₂O₂S:Eu), lanthanum oxysulphide:europium(La₂O,S:Eu), and gadolinium oxysulphide:promethium, cerium, fluorine(Gd₂O₂S:Pr,Ce,F), YPO₄:Nd, LaPO₄:Pr, (Ca,Mg)SO₄:Pb, YBO₃:Pr, Y₂SiO₅:Pr,Y₂Si₂O₇:Pr, SrLi₂SiO₄:Pr,Na, and CaLi₂SiO₄:Pr.

In other aspects of the invention, the downconverting energy modulationagent can be near-infrared (NIR) downconversion (DC) phosphors such asKSrPO₄:EU²⁺, Pr³⁺, or NaGdF₄:Eu or Zr₂SiO₄:Tb³⁺,Yb³⁺ or β-NaGdF₄co-doped with Ce³⁺ and Tb³⁺ ions or Gd₂O₂S:Tm or BaYF₃:Eu³⁺ or otherdown converters which emit NIR from visible or UV light exposure (as ina cascade from x-ray to UV to NIR) or which emit NIR directly afterx-ray or e-beam exposure.

In one aspect of the invention, an up converting energy modulation agentcan be at least one of Y₂O₃, Y₂O₂S, NaYF₄, NaYbF₄, YAG, YAP, Nd₂O₃,LaF₃, LaCl₃, La₂O₃, TiO₂, LuPO₄, YVO₄, YbF₃, YF₃, Na-doped YbF₃, or SiO₂or alloys or layers thereof.

In one aspect of the invention, the energy modulation agents can be usedsingly or in combination with other down converting or up convertingmaterials.

Below is a list of X-ray phosphors which can be used in the presentinvention along with their corresponding peak emission values.

TABLE 14 Emission Spectrum Peak X-ray Absorption Microstructure EmissionEmiss Eff K-edge Specific Crystal # Phosphor (nm) Eff (%) (Z) (keV)Gravity Structure Hygroscopic 1 BaFCl:Eu²⁺ 380 13 49.3 37.38 4.7Tetragonal N 2 BaSO₄−:Eu²⁺ 390 6 45.5 37.38 4.5 Rhombic N 3 LaOBr:Tm³⁺360, 460 14 49.3 38.92 6.3 Tetragonal N 4 YTaO₄ 337 59.8 67.42 7.5Monolithic N 5 YTaO₄:Nb (*) 410 11 59.8 67.42 7.5 Monolithic N 6 CaWO₄420 5 61.8 69.48 6.1 Tetragonal N 7 LaOBr:Tb³⁺ 420 20 49.3 38.92 6.3Tetragonal N 8 Y₂O₂S:Tb³⁺ 420 18 34.9 17.04 4.9 Hexgonal N 9 ZnS:Ag 45017 26.7  9.66 3.9 Hexgonal N 10 (Zn, Cd)S:Ag 530 19 38.4 9.66/26.7 4.8Hexgonal N 11 Gd₂O₂S:Tb³⁺ 545 13 59.5 50.22 7.3 Hexgonal N 12La₂O₂S:Tb³⁺ 545 12.5 52.6 38.92 6.5 Hexgonal N

Various plastic scintillators, plastic scintillator fibers and relatedmaterials are made of polyvinyltoluene or styrene and fluors. Thesematerials could be used in the present invention especially ifencapsulated or otherwise chemically isolated from the target structureso not as to be dissolved or otherwise deteriorated by the fluids of thetarget structure. These and other formulations are commerciallyavailable, such as from Saint Gobain Crystals, as BC-414, BC-420,BC-422, or BCF-10.

TABLE 15 Product Peak Emission Phosphor Reference (nm) Organic BC-414392 Organic BC-420 391 Organic BC-422 370

Other polymers are able to emit in the visible range and these include:

TABLE 16 Phosphor Product Peak Emission # of Photons (Fiber Forms)Reference (nm) Per MeV Organic BCF-10 432 8000 Organic BC-420 435 8000Organic BC-422 492 8000

Table 17 shows a wide variety of energy modulation agents which can beused in this invention.

TABLE 17 Emission Spectrum X-Ray Peak Absorption Phosphor Emission EmissK-edge Specific Crystal Color (nm) Eff (%) Eff (Z) (keV) GravityStructure Hygroscopic Zn3(PO4)2:Ti+ 310 N BaF2 310 Slightly Csl 315 NCa3(PO4)2:Ti+ 330 N YTaO4 337 59.8 67.42 7.5 Monolithic N Csl:Na 338 YBaSi2O5:Pb2+ 350 N Borosilicate 350 N LaCl3(Ce) 350 Y SrB4O7F:Eu2+ 360 NRbBr:Ti+ 360 ? (Ba, Sr, Mg)3Si2O7:Pb2+ 370 N YaiO3:Ce3+ 370 N BAlO3:Ce3+370 N BC-422 370 Organic ? BaFCl:Eu2+ 380 13 49.3 37.38 4.7 Tetragonal NBaSO4−:Eu2+ 390 6 45.5 37.38 4.5 Rhombic N BaFBr:Eu2+ 390 ? BC-420 391Organic ? BC-414 392 Organic ? SrMgP2O7:Eu2+ 394 N BaBr2:Eu2+ 400 N (Sr,Ba)Al2Si2O8:Eu2+ 400 N YTaO4:Nb(*) 410 11 59.8 67.42 7.5 Monolithic NY2SiO5:Ce3+ 410 N CaWO4 420 5 61.8 69.48 6.1 Tetragonal N LaOBr:Tb3+ 42020 49.3 38.92 6.3 Tetragonal N Y2O2S:Tb3+ 420 18 34.9 17.04 4.9 HexgonalN Lu2SiO5:Ce3+ 420 N Lul.8Y0.2SiO5:Ce 420 N Zn5:Ag 450 17 26.7  9.66 3.9Hexgonal N CdWO4 475 Slightly Bi4Ge3O12(BGO) 480 N (Zn, Cd)S:Ag 530 1938.4 9.66/26.7 4.8 Hexgonal N Gd2O25:TB3+ 545 13 59.5 50.22 7.3 HexgonalN La2O25:Tb3+ 545 12.5 52.6 38.92 6.5 Hexgonal N Y3Al5O12(Ce) 550 NLaOBr:Tm3+ 360, 460 14 49.3 38.92 6.3 Tetragonal N CaF2(Eu) 435/300 N

By selection of one or more of the phosphors noted above (or othersknown in the art), the present invention permits one to provide in avicinity of or within a target structure one or more light emitterscapable of emitting different wavelengths corresponding to respectivebiological responses, and permits the activation of one or morebiological responses in the target structure depending on at least oneor more different wavelengths of light generated internally or providedinternally within the subject, wherein the different wavelengthsactivate the respective biological responses (i.e., selectiveactivation).

Another embodiment to deliver the energy modulation agent-PA drugsinvolves the use of ferritin and apoferritin compounds. There isincreasing interest in ligand-receptor-mediated delivery systems due totheir non-immunogenic and site-specific targeting potential to theligand-specific bio-sites. Platinum anticancer drug have beenencapsulated in apoferritin. Ferritin, the principal iron storagemolecule in a wide variety of organisms, can also be used as a vehiclefor targeted drug delivery. It contains a hollow protein shell,apoferritin, which can contain up to its own weight of hydrous ferricoxide-phosphate as a microcrystalline micelle. The 24 subunits offerritin assemble automatically to form a hollow protein cage withinternal and external diameters of 8 and 12 nm, respectively. Eighthydrophilic channels of about 0.4 nm, formed at the intersections ofsubunits, penetrate the protein shell and lead to the protein cavity. Avariety of species such as gadolinium (Gd³⁺) contrast agents,desferrioxamine B, metal ions, and nanoparticles of iron salts can beaccommodated in the cage of apoferritin. Various metals such as iron,nickel, chromium and other materials have been incorporated intoapoferritin. Zinc selenide nanoparticles (ZnSe NPs) were synthesized inthe cavity of the cage-shaped protein apoferritin by designing a slowchemical reaction system, which employs tetraaininezinc ion andselenourea. The chemical synthesis of ZnSe NPs was realized in aspatially selective manner from an aqueous solution, and. ZnSe coreswere formed in almost all apoferritin cavities with little bulkprecipitation.

Some of the phosphors used for psoralen activation have a high atomicmass with a high probability of interaction with the X-Ray photons. As aresult, the phosphors are also X-Ray contrasting agents. An image can bederived through X-Ray imaging and can be used to pin-point the locationof the tumor.

In a further embodiment, methods in accordance with the presentinvention may further include adding an additive to alleviate treatmentside-effects. Exemplary additives may include, but are not limited to,antioxidants, adjuvant, or combinations thereof In one exemplaryembodiment, psoralen is used as the activatable pharmaceutical agent,UV-A is used as the activating energy, and antioxidants are added toreduce the unwanted side-effects of irradiation.

The activatable pharmaceutical agent and derivatives thereof as well asthe energy modulation agent, can be incorporated into pharmaceuticalcompositions suitable for administration. Such compositions typicallycomprise the activatable pharmaceutical agent and a pharmaceuticallyacceptable carrier. The pharmaceutical composition also comprises atleast one additive having a complementary therapeutic or diagnosticeffect, wherein the additive is one selected from an antioxidant, anadjuvant, or a combination thereof

As used herein, “pharmaceutically acceptable carrier” is intended toinclude any and all solvents, dispersion media, coatings, antibacterialand antifungal agents, isotonic and absorption delaying agents, and thelike, compatible with pharmaceutical administration. The use of suchmedia and agents for pharmaceutically active substances is well known inthe art. Except insofar as any conventional media or agent isincompatible with the active compound, use thereof in the compositionsis contemplated. Supplementary active compounds can also be incorporatedinto the compositions. Modifications can be made to the compound of thepresent invention to affect solubility or clearance of the compound.These molecules may also be synthesized with D-amino acids to increaseresistance to enzymatic degradation. If necessary, the activatablepharmaceutical agent can be co-administered with a solubilizing agent,such as cyclodextran.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration. Examples of routesof administration include parenteral, e.g., intravenous, intradermal,subcutaneous, oral (e.g., inhalation), transdermal (topical),transmucosal, rectal administration, and direct injection into theaffected area, such as direct injection into a tumor. Solutions orsuspensions used for parenteral, intradermal, or subcutaneousapplication can include the following components: a sterile diluent suchas water for injection, saline solution, fixed oils, polyethyleneglycols, glycerin, propylene glycol or other synthetic solvents;antibacterial agents such as benzyl alcohol or methyl parabens;antioxidants such as ascorbic acid or sodium bisulfite; chelating agentssuch as ethylenediaminetetraacetic acid; buffers such as acetates,citrates or phosphates, and agents for the adjustment of tonicity suchas sodium chloride or dextrose. The pH can be adjusted with acids orbases, such as hydrochloric acid or sodium hydroxide. The parenteralpreparation can be enclosed in ampoules, disposable syringes or multipledose vials made of glass or plastic.

Pharmaceutical compositions suitable here for injectable use includesterile aqueous solutions (where water soluble) or dispersions andsterile powders for the extemporaneous preparation of sterile injectablesolutions or dispersion. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, orphosphate buffered saline (PBS). In all cases, the composition must besterile and should be fluid to the extent that easy syringabilityexists. It must be stable under the conditions of manufacture andstorage and must be preserved against the contaminating action ofmicroorganisms such as bacteria and fungi. The carrier can be a solventor dispersion medium containing, for example, water, ethanol, polyol(for example, glycerol, propylene glycol. and liquid polyethyleneglycol, and the like), and suitable mixtures thereof. The properfluidity can be maintained, for example, by the use of a coating such aslecithin, by the maintenance of the required particle size in the caseof dispersion and by the use of surfactants. Prevention of the action ofmicroorganisms can be achieved by various antibacterial and antifungalagents, for example, parabens, chlorobutanol, phenol, ascorbic acid,thimerosal, and the like. In many cases, it will be preferable toinclude isotonic agents, for example, sugars, polyalcohols such asmanitol, sorbitol, sodium chloride in the composition. Prolongedabsorption of the injectable compositions can be brought about byincluding in the composition an agent which delays absorption, forexample, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle that contains abasic dispersion medium and the required other ingredients from thoseenumerated. above. In the case of sterile powders for the preparation ofsterile injectable solutions, methods of preparation are vacuum dryingand freeze-drying that yields a powder of the active ingredient plus anyadditional desired ingredient from a previously sterile-filteredsolution thereof.

In one embodiment, the active compounds (phosphors and UVADEX) areprepared with carriers that will protect the compound against rapidelimination from the body, such as a controlled release formulation,including implants and microencapsulated delivery systems.Biodegradable, biocompatible polymers can be used, such as ethylenevinyl acetate, polyanhydrides, polyglycolic acid, collagen,polyorthoesters, and polylactic acid. Methods for preparation of suchformulations will be apparent to those skilled in the art. The materialscan also be obtained commercially. Liposomal suspensions (includingliposomes targeted to infected cells with monoclonal antibodies to viralantigens) can also be used as pharmaceutically acceptable carriers.These can be prepared according to methods known to those skilled in theart, for example, as described in U.S. Pat. No. 4,522,811.

As shown above, the pharmaceutical compositions can be included in acontainer, pack, or dispenser together with instructions foradministration. The instructions could be in any desired form, includingbut not limited to, printed on a kit insert, printed on one or morecontainers, as well as electronically stored instructions provided on anelectronic storage medium, such as a computer readable storage medium.Also optionally included is a software package on a computer readablestorage medium that permits the user to integrate the information andcalculate a control dose, to calculate and control intensity of theirradiation source.

It will also be understood that the order of administering the differentagents is not particularly limited. Thus in some embodiments theactivatable pharmaceutical agent may be administered before thephosphors comprising the novel phosphor-containing drug activator, whilein other embodiments the phosphors may be administered prior to theactivatable pharmaceutical agent. It will be appreciated that differentcombinations of ordering may be advantageously employed depending onfactors such as the absorption rate of the agents, the localization andmolecular trafficking properties of the agents, and otherpharmacokinetics or pharmacodynamics considerations.

STATEMENTS OF THE INVENTION

The following numbered statements of the invention provide descriptionsof different aspects of the invention and are not intended to limit theinvention beyond that of the appended claims. While presented innumerical order, the present invention recognized that the features setforth below can be readily combined with each other as part of thisinvention. Furthermore, the features set forth below can be readilycombined with any of the elements of the specification discussed above.

1. A phosphor-containing drug activator, comprising:

-   -   an admixture or suspension of two or more phosphors capable of        emitting ultraviolet and visible light upon interaction with        x-rays;    -   said two or more phosphors comprising Zn₂SiO₄:Mn²⁺ and        (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺) at a ratio NP-200:GTP-4300 of        from 1:10 to 10:1;    -   each of said two phosphors having at least one coating selected        from the group consisting of an ethylene cellulose coating and a        diamond-like carbon coating; and, optionally in the case of the        suspension, a pharmaceutically acceptable carrier. As noted        above, other phosphors and phosphor combinations and ratios can        be used in the present invention.

2. The activator of statement 1, wherein said ratio ranges from 1:5 to5:1.

3. The activator of statement 1, wherein said ratio ranges from 1:2 to2:1.

4. The activator of statement 1, wherein said ratio is about 1:2.

5. The activator of statement 1, further comprising 8 MOP.

6. The activator of statement 1, wherein said two or more phosphors havea composition that emits said ultraviolet and visible light atwavelengths which activate 8 MOP.

7. The activator of statement 5, wherein said Zn₂SiO₄:Mn²⁺ phosphor hascathodoluminescent emission peaks at 160 nm, 360 nm, and 525 nm.

8. The activator of statement 5, wherein said (3Ca₃(PO₄)₂Ca(F, Cl)₂:Sb³⁺, Mn²) phosphor has a cathodoluminescent emission edge at 400 nm anda cathodoluminescent emission peaks at 570 nm.

9. The activator of statement 1, wherein each of said two or morephosphors has a first coating comprising said ethylene cellulose coatingon the phosphor, and a second outer coating comprising said diamond-likecarbon coating on said first coating.

10. The activator of statement 1, wherein each of said two or morephosphors has an outer coating of said ethylene cellulose coating.

11. The activator of statement 1, wherein each of said two or morephosphors has an outer coating of said diamond-like carbon coating.

12. The activator of statement 1 wherein said ethylene cellulose coatingis present and has a thickness between 10 and 100 nm.

13. The activator of statement 1, wherein said ethylene cellulosecoating is present and has a thickness between 30 and 60 nm.

14. The activator of statement 1, wherein said diamond-like carboncoating is present and has a thickness between 50 and 200 nm.

15. The activator of statement 1, wherein said diamond-like carboncoating is present and has a thickness between 75 and 125 nm.

16. The activator of statement 1, wherein said Zn₂SiO₄:Mn²⁺ phosphor hasa size between 0.05 and 100 microns.

17. The activator of statement 1 wherein said Zn₂SiO₄:Mn²⁺ phosphor hasa size between 0.1 and 50 microns.

18. The activator of statement 1, wherein said Zn₂SiO₄:Mn²⁺ phosphor hasa size between 0.5 and 20 microns.

19. The activator of statement 1, wherein said (3Ca₃(PO₄)2Ca(F, Cl)₂:S³⁺, Mn²⁺) phosphor has a size between 0.05 and 100 microns.

20. The activator of statement 1, wherein said (3Ca₃(PO₄)2Ca(F, Cl)₂:Sb³⁺, Mn²⁺) phosphor has a size between 0.1 and 50 microns.

21. The activator of statement 1, wherein said (3Ca₃(PO₄)2Ca(F, Cl)₂:Sb³⁺, Mn²⁺) phosphor has a size between 0.5 and 20 microns.

22. The activator of statement 1, which is a suspension and wherein saidtwo or more phosphors and the pharmaceutically acceptable carriercomprise a sterile solution.

23. The activator of statement 22, wherein a ratio of phosphor weight tovolume of the sterile suspension ranges from 1 to 50 mg/mL.

24. The activator of statement 22, wherein a ratio of phosphor weight tovolume of the sterile suspension ranges from 5 to 25 mg/mL.

25. The activator of statement 22, wherein a ratio of phosphor weight tovolume of the sterile suspension ranges from 8 to 10 mg/mL.

26. The activator of statement 1, wherein the diamond-like carboncoating is present and has a water-droplet contact angle between about90 and 110°.

27. The activator of statement 1, further comprising an additiveproviding a therapeutic or diagnostic effect.

28. The activator of statement 27, wherein the additive comprises atleast one of an antioxidant, an adjuvant, or a combination thereof.

29. The activator of statement 27, wherein the additive comprises animage contrast agent.

30. The activator of statement 27, wherein the additive comprises avaccine.

31. A system for treating a disease in a subject in need thereof,comprising:

-   -   the activator of one of statements 1-30 or combinations thereof,    -   a photoactivatable drug comprising 8 MOP;    -   one or more devices which infuse the photoactivatable drug and        the activator including the pharmaceutically acceptable carrier        into a diseased site in the subject; and    -   an x-ray source which is controlled to deliver a dose of x-rays        to the subject for production of the ultraviolet and visible        light inside the subject to activate the photoactivatable drug        and induce a persistent therapeutic response, said dose        comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy        to the tumor.

32. The system of statement 31, wherein the photoactivatable drug isuntethered from the two or more phosphors.

33. The system of statement 31, wherein the one or more devicesadminister the photoactivatable drug in accordance with a volume of thediseased site.

34. The system of statement 31, wherein an amount of the phosphors inthe pharmaceutical carrier ranges from 0.1 to 0.66 milligrams ofphosphor per cm³ of the volume of the diseased site, and a concentrationof the photoactivatable drug in the pharmaceutical carrier ranges from10 μg/mL to 50 μg/mL.

35. The system of statement 31, wherein the x-ray source is configuredto generate x-rays from a peak applied cathode voltage at or below 300kVp, at or below 200 kVp, at or below 120 kVp, at or below 105 kVp, ator below 80 kVp, at or below 70 kVp, at or below 60 kVp, at or below 50kVp, at or below 40 kVp, at or below 30 kVp, at or below 20 kVp, at orbelow 10 kVp, or at or below 5 kVp.

36. The system of statement 31, wherein the dose of x-rays comprises anamount to cause an auto-vaccine effect in the human or animal body.

37. The system of statement 31, wherein the x-ray source is controlledduring a booster treatment to repeat on a periodic basis a treatment ofthe diseased site.

38. The system of statement 37, wherein, in the booster treatment, atleast one of phosphor concentration, photoactivatable drugconcentration, and the radiation dose is increased by a factor of atleast two times, five times, or ten times respective initial values.

39. The system of statement 37, wherein the booster treatment producespsoralen-modified cancer cells or X-ray modified cancer cells.

40. The system of statement 37, wherein the booster treatment producesradiation damaged cancer cells.

41. The system of statement 37, wherein a period between boostertreatments is delayed according to a tolerance level of the human oranimal body for radiation-modified. cells generated during the boostertreatment.

42. The system of statement 31, wherein the x-ray source directs x-raysto at least one of a tumor or a malignancy.

43. The system of statement 31, wherein the x-ray source directs x-raysto at least one of a eukaryotic cell, a prokaryotic cell, a subcellularstructure, an extracellular structure, a virus or priori, a cellulartissue, a cell membrane, a nuclear membrane, cell nucleus, nucleic acid,mitochondria, ribosome, or other cellular organelle.

44. The system of statement 31, wherein the x-ray source directs x-raysto a diseased site in a pulsed manner having an on and off time.

45. The system of statement 44, wherein the x-ray source directs x-raysto the diseased site such that the on time activates the phosphor andthe off time is long enough for decay of phosphor light emission.

46. The system of statement 31, wherein the x-ray source directs x-raysto a tumor or a malignancy in a pulsed manner having an on and off time.

47. The system of statement 46, wherein the x-ray source directs x-raysto the tumor or the malignancy such that the on time activates thephosphor and the off time is long enough for decay of phosphor lightemission.

48. The system of statement 31. wherein the x-ray source directs x-raysto the diseased site according to a predetermined radiation protocolsuch that a predetermined change occurs in the diseased site.

49. The system of statement 48, wherein

-   -   said predetermined change comprises at least one of 1) affects a        prion, viral, bacterial, fungal, or parasitic infection, 2)        comprises at least one of one of tissue regeneration,        inflammation relief, pain relief, immune system fortification,        or 3) comprises at least changes in cell membrane permeability,        up-regulation and down-regulation of adenosine triphosphate and        nitric oxide.

50. The system of statement 31, wherein the x-ray source is controlledsuch that a dose of about 1 Gy is delivered using twenty one x-raypulses spaced apart by 10 seconds; and, each x-ray pulse of 800 ms isdelivered from the x-ray source set at a voltage of 80 kV and anamperage of 200 mA.

51. A method for treating a disease in a subject in need thereof usingthe system of statement 31, comprising:

-   -   infusing the photoactivatable drug, and the activator including        the pharmaceutically acceptable carrier into a diseased site in        the subject; and    -   delivering a dose of x-rays to the subject for production of the        ultraviolet and visible light inside the subject to activate the        photoactivatable drug and induce a persistent therapeutic        response, said dose comprising a pulsed sequence of x-rays        delivering from 0.5-2 Gy to the tumor.

52. The method of statement 51, wherein infusing comprises infusing thephotoactivatable drug untethered from the two or more phosphors.

53. The method of statement 51, wherein infusing comprises administeringthe photoactivatable drug in accordance with a volume of the diseasedsite.

54. The method of statement 51, wherein

-   -   an amount of the phosphors in the pharmaceutical carrier ranges        from 0.1 to 0.66 milligrams of phosphor per cm³ of the volume of        the diseased site, and    -   a concentration of the photoactivatable drug in the        pharmaceutical carrier ranges from 10 μg/mL to 50 μg/mL.

55. The method of statement 51, wherein delivering comprises generatingx-rays from a peak applied cathode voltage at or below 300 kVp, at orbelow 200 kVp, at or below 120 kVp, at or below 105 kVp, at or below 80kVp, at or below 70 kVp, at or below 60 kVp, at or below 50 kVp, at orbelow 40 kVp, at or below 30 kVp, at or below 20 kVp, at or below 10kVp, or at or below 5 kVp.

56. The method of statement 51, wherein delivering comprises providing adose of x-rays in an amount to cause an auto-vaccine effect in the humanor animal body.

57. The method of statement 51, wherein delivering comprises providing abooster treatment Which repeats on a periodic basis a treatment of thediseased site.

58. The method of statement 57, wherein, in the booster treatment, atleast one of phosphor concentration, photoactivatable drugconcentration, and the radiation dose is increased by a factor of atleast two times, five times, or ten times respective initial values.

59. The method of statement 57, wherein the booster treatment producespsoralen-modified cancer cells or X-ray modified cancer cells.

60. The method of statement 57, wherein the booster treatment producesradiation damaged cancer cells.

61. The method of statement 57, wherein a period between boostertreatments is delayed according to a tolerance level of the human oranimal body for radiation-modified. cells generated during the boostertreatment.

62. The method of statement 51, wherein delivering comprises directingx-rays to at least one of a tumor or a malignancy.

63. The method of statement 51, wherein delivering comprises directingx-rays to at least one of a eukaryotic cell, a prokaryotic cell, asubcellular structure, an extracellular structure, a virus or prion, acellular tissue, a cell membrane, a nuclear membrane, cell nucleus,nucleic acid, mitochondria, ribosome, or other cellular organelle.

64. The method of statement 51, wherein delivering comprises directingx-rays to a diseased site in a pulsed manner having an on and off time.

65. The method of statement 64, wherein delivering comprises directingx-rays to the diseased site such that the on time activates the phosphorand the off time is long enough for decay of phosphor light emission.

66. The method of statement 51, wherein delivering comprises directingx-rays to a tumor or a malignancy in a pulsed manner having an on andoff time.

67. The method of statement 66, wherein delivering comprises directingx-rays to the tumor or the malignancy such that the on time activatesthe phosphor and the off time is long enough for decay of phosphor lightemission.

68. The method of statement 51, wherein delivering comprises directingx-rays to the diseased site according to a predetermined radiationprotocol such that a predetermined change occurs in the diseased site.

69. The method of statement 68, wherein

-   -   said predetermined change comprises at least one of 1) affects a        prion, viral, bacterial, fungal, or parasitic infection, 2)        comprises at least one of one of tissue regeneration,        inflammation relief, pain relief, immune system fortification,        or 3) comprises at least changes in cell membrane permeability,        up-regulation and down-regulation of adenosine triphosphate and        nitric oxide.

70. The method of statement 51, wherein delivering comprises providing adose of about 1 Gy using twenty one x-ray pulses spaced apart by 10seconds and, each x-ray pulse of 800 ms is delivered from an x-raysource set at a voltage of 80 kV and an amperage of 200 mA.

Numerous modifications and variations of the invention are possible inlight of the above teachings. It is therefore to be understood thatwithin the scope of the appended claims, the invention may be practicedotherwise than as specifically described herein. All of thepublications, references, patents, patent applications, and otherdocuments identified above are incorporated by reference herein in theirentirety.

The invention claimed is:
 1. A phosphor-containing drug activator,comprising: an admixture of two or more phosphors capable of emittingultraviolet and visible light upon interaction with x-rays; said two ormore phosphors comprising Zn₂SiO₄:Mn²⁺ and (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺,Mn²⁺) at a ratio (Zn₂SiO₄:Mn²⁺):(3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺)) offrom 1:10 to 10:1; each of said two phosphors having at least onecoating selected from the group consisting of an ethyl cellulose coatingand a diamond-like carbon coating.
 2. The phosphor-containing drugactivator of claim 1, wherein said ratio ranges from 1:5 to 5:1.
 3. Thephosphor-containing drug activator of claim 1, wherein said ratio rangesfrom 1:2 to 2:1.
 4. The phosphor-containing drug activator of claim 1,wherein said ratio is about 1:2.
 5. The phosphor-containing drugactivator of claim 1, wherein said two or more phosphors have acomposition that emits said ultraviolet and visible light at wavelengthswhich activate 8-methoxypsoralen (8-MOP).
 6. The phosphor-containingdrug activator of claim 1, wherein said Zn₂SiO₄:Mn²⁺ phosphor hascathodoluminescent emission peaks at 160 nm, 360 nm, and 525 nm.
 7. Thephosphor-containing drug activator of claim 1, wherein said(3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a cathodoluminescentemission edge at 400 nm and a cathodoluminescent emission peaks at 570nm.
 8. The phosphor-containing drug activator of claim 1, wherein eachof said two or more phosphors has a first coating comprising said ethylcellulose coating on the phosphor, and a second outer coating comprisingsaid diamond-like carbon coating on said first coating.
 9. Thephosphor-containing drug activator of claim 1, wherein each of said twoor more phosphors has an outer coating of said ethyl cellulose coating.10. The phosphor-containing drug activator of claim 1, wherein each ofsaid two or more phosphors has an outer coating of said diamond-likecarbon coating.
 11. The phosphor-containing drug activator of claim 1wherein said ethyl cellulose coating is present and has a thicknessbetween 10 and 100 nm.
 12. The phosphor-containing drug activator ofclaim 1, wherein said ethyl cellulose coating is present and has athickness between 30 and 60 nm.
 13. The phosphor-containing drugactivator of claim 1, wherein said diamond-like carbon coating ispresent and has a thickness between 50 and 200 nm.
 14. Thephosphor-containing drug activator of claim 1, wherein said diamond-likecarbon coating is present and has a thickness between 75 and 125 nm. 15.The phosphor-containing drug activator of claim 1, wherein saidZn₂SiO₄:Mn²⁺ phosphor has a size between 0.05 and 100 microns.
 16. Thephosphor-containing drug activator of claim 1, wherein said Zn₂SiO₄:Mn²⁺phosphor has a size between 0.1 and 50 microns.
 17. Thephosphor-containing drug activator of claim 1, wherein said Zn₂SiO₄:Mn²⁺phosphor has a size between 0.5 and 20 microns.
 18. Thephosphor-containing drug activator of claim 1, wherein said(3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a size between 0.05 and100 microns.
 19. The phosphor-containing drug activator of claim 1,wherein said (3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a sizebetween 0.1 and 50 microns.
 20. The phosphor-containing drug activatorof claim 1, wherein said (3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³+, Mn²+) phosphor hasa size between 0.5 and 20 microns.
 21. The phosphor-containing drugactivator of claim 1, wherein the diamond-like carbon coating is presentand has a water-droplet contact angle between about 90 and 110°.
 22. Asuspension of a phosphor-containing drug activator, comprising: two ormore phosphors capable of emitting ultraviolet and visible light uponinteraction with x-rays; said two or more phosphors comprisingZn₂SiO₄:Mn²⁺ and (3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺) at a ratio(Zn₂SiO₄:Mn²⁺):(3Ca₃(PO₄)₂Ca(F, Cl)₂: Sb³⁺, Mn²⁺)) of from 1:10 to 10:1;each of said two phosphors having at least one coating selected from thegroup consisting of an ethyl cellulose coating and a diamond-like carboncoating; and a pharmaceutically acceptable carrier.
 23. The suspensionof claim 22, wherein said ratio ranges from 1:5 to 5:1.
 24. Thesuspension of claim 22, wherein said ratio ranges from 1:2 to 2:1. 25.The suspension of claim 22, wherein said ratio is about 1:2.
 26. Thesuspension of claim 22, further comprising 8-methoxypsoralen (8-MOP).27. The suspension of claim 22, wherein said two or more phosphors havea composition that emits said ultraviolet and visible light atwavelengths which activate 8-methoxypsoralen (8-MOP).
 28. The suspensionof claim 22, wherein said Zn₂SiO₄:Mn²⁺ phosphor has cathodoluminescentemission peaks at 160 nm, 360 nm, and 525 nm.
 29. The suspension ofclaim 22, wherein said (3Ca₃(PO₄)2Ca(F, C1)₂: Sb³⁺, Mn²⁺) phosphor has acathodoluminescent emission edge at 400 nm and a cathodoluminescentemission peaks at 570 nm.
 30. The suspension of claim 22, wherein eachof said two or more phosphors has a first coating comprising said ethylcellulose coating on the phosphor, and a second outer coating comprisingsaid diamond-like carbon coating on said first coating.
 31. Thesuspension of claim 22, wherein each of said two or more phosphors hasan outer coating of said ethyl cellulose coating.
 32. The suspension ofclaim 22, wherein each of said two or more phosphors has an outercoating of said diamond-like carbon coating.
 33. The suspension of claim22, wherein said ethyl cellulose coating is present and has a thicknessbetween 10 and 100 nm.
 34. The suspension of claim 22, wherein saidethyl cellulose coating is present and has a thickness between 30 and 60nm.
 35. The suspension of claim 22, wherein said diamond-like carboncoating is present and has a thickness between 50 and 200 nm.
 36. Thesuspension of claim 22, wherein said diamond-like carbon coating ispresent and has a thickness between 75 and 125 nm.
 37. The suspension ofclaim 22, wherein said Zn₂SiO₄:Mn²⁺ phosphor has a size between 0.05 and100 microns.
 38. The suspension of claim 22, wherein said Zn₂SiO₄:Mn²⁺phosphor has a size between 0.1 and 50 microns.
 39. The suspension ofclaim 22, wherein said Zn₂SiO₄:Mn²⁺ phosphor has a size between 0.5 and20 microns.
 40. The suspension of claim 22, wherein said(3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a size between 0.05 and100 microns.
 41. The suspension of claim 22, wherein said(3Ca₃(PO₄)2Ca(F, Cl)₂: Sb³⁺, Mn²⁺) phosphor has a size between 0.1 and50 microns.
 42. The suspension of claim 1, wherein said (3Ca₃(PO₄)2Ca(F,Cl)₂: Sb³⁺, Mn²⁺) phosphor has a size between 0.5 and 20 microns. 43.The suspension of claim 22, wherein said two or more phosphors and thepharmaceutically acceptable carrier comprise a sterile solution.
 44. Thesuspension of claim 43, wherein a ratio of phosphor weight to volume ofthe sterile suspension ranges from 1 to 50 mg/mL.
 45. The suspension ofclaim 43, wherein a ratio of phosphor weight to volume of the sterilesuspension ranges from 5 to 25 mg/mL.
 46. The suspension of claim 43,wherein a ratio of phosphor weight to volume of the sterile suspensionranges from 8 to 10 mg/mL.
 47. The suspension of claim 22, wherein thediamond-like carbon coating is present and has a water-droplet contactangle between about 90 and 110°.
 48. The suspension of claim 22, whereinthe pharmaceutically acceptable carrier further comprises an additiveproviding a therapeutic or diagnostic effect.
 49. The suspension ofclaim 48, wherein the additive comprises at least one of an antioxidant,an adjuvant, or a combination thereof.
 50. The suspension of claim 48,wherein the additive comprises an image contrast agent.
 51. Thesuspension of claim 48, wherein the additive comprises a vaccine.
 52. Asystem for treating a disease in a subject in need thereof, comprising:the suspension of claim 22; a photoactivatable drug comprising8-methoxypsoralen (8-MOP); one or more devices which infuse thephotoactivatable drug and the suspension including the pharmaceuticallyacceptable carrier into a diseased site in the subject; and an x-raysource which is controlled to deliver a dose of x-rays to the subjectfor production of the ultraviolet and visible light inside the subjectto activate the photoactivatable drug and induce a persistenttherapeutic response, said dose comprising a pulsed sequence of x-raysdelivering from 0.5-2 Gy to the tumor.
 53. The system of claim 52,wherein the photoactivatable drug is untethered from the two or morephosphors.
 54. The system of claim 52, wherein the one or more devicesadminister the photoactivatable drug in accordance with a volume of thediseased site.
 55. The system of claim 52, wherein an amount of thephosphors in the pharmaceutical carrier ranges from 0.1 to 0.66milligrams of phosphor per cm³ of the volume of the diseased site, and aconcentration of the photoactivatable drug in the pharmaceutical carrierranges from 10 μg/mL to 50 μg/mL.
 56. The system of claim 52, whereinthe x-ray source is configured to generate x-rays from a peak appliedcathode voltage at or below 300 kVp, at or below 200 kVp, at or below120 kVp, at or below 105 kVp, at or below 80 kVp, at or below 70 kVp, ator below 60 kVp, at or below 50 kVp, at or below 40 kVp, at or below 30kVp, at or below 20 kVp, at or below 10 kVp, or at or below 5 kVp. 57.The system of claim 52, wherein the dose of x-rays comprises an amountto cause an auto-vaccine effect in the human or animal body.
 58. Thesystem of claim 52, wherein the x-ray source is controlled during abooster treatment to repeat on a periodic basis a treatment of thediseased site.
 59. The system of claim 58, wherein, in the boostertreatment, at least one of phosphor concentration, photoactivatable drugconcentration, and the radiation dose is increased by a factor of atleast two times, five times, or ten times respective initial values. 60.The system of claim 58, wherein the booster treatment producespsoralen-modified cancer cells or X-ray modified cancer cells.
 61. Thesystem of claim 58, wherein the booster treatment produces radiationdamaged cancer cells.
 62. The system of claim 58, wherein a periodbetween booster treatments is delayed according to a tolerance level ofthe human or animal body for radiation-modified cells generated duringthe booster treatment.
 63. The system of claim 52, wherein the x-raysource directs x-rays to at least one of a tumor or a malignancy. 64.The system of claim 52, wherein the x-ray source directs x-rays to atleast one of a eukaryotic cell, a prokaryotic cell, a subcellularstructure, an extracellular structure, a virus or prion, a cellulartissue, a cell membrane, a nuclear membrane, cell nucleus, nucleic acid,mitochondria, ribosome, or other cellular organelle.
 65. The system ofclaim 52, wherein the x-ray source directs x-rays to a diseased site ina pulsed manner having an on and off time.
 66. The system of claim 65,wherein the x-ray source directs x-rays to the diseased site such thatthe on time activates the phosphor and the off time is long enough fordecay of phosphor light emission.
 67. The system of claim 52, whereinthe x-ray source directs x- rays to a tumor or a malignancy in a pulsedmanner having an on and off time.
 68. The system of claim 67, whereinthe x-ray source directs x-rays to the tumor or the malignancy such thatthe on time activates the phosphor and the off time is long enough fordecay of phosphor light emission.
 69. The system of claim 52, whereinthe x-ray source directs x-rays to the diseased site according to apredetermined radiation protocol such that a predetermined change occursin the diseased site.
 70. The system of claim 69, wherein saidpredetermined change comprises at least one of 1) affects a prion,viral, bacterial, fungal, or parasitic infection, 2) comprises at leastone of one of tissue regeneration, inflammation relief, pain relief,immune system fortification, or 3) comprises at least changes in cellmembrane permeability, up-regulation and down-regulation of adenosinetriphosphate and nitric oxide.
 71. The system of claim 52, wherein thex-ray source is controlled such that a dose of about 1 Gy is deliveredusing twenty one x-ray pulses spaced apart by 10 seconds; and, eachx-ray pulse of 800 ms is delivered from the x-ray source set at avoltage of 80 kV and an amperage of 200 mA.
 72. A method for treating adisease in a subject in need thereof using the system of claim 52,comprising: infusing the 8-methoxypsoralen (8-MOP) and the suspensionincluding the pharmaceutically acceptable carrier into a diseased sitein the subject; and delivering a dose of x-rays to the subject forproduction of the ultraviolet and visible light inside the subject toactivate the photoactivatable drug and induce a persistent therapeuticresponse, said dose comprising a pulsed sequence of x-rays deliveringfrom 0.5-2 Gy to the tumor.
 73. The method of claim 72, wherein infusingcomprises infusing the photoactivatable drug untethered from the two ormore phosphors.
 74. The method of claim 72, wherein infusing comprisesadministering the photoactivatable drug in accordance with a volume ofthe diseased site.
 75. The method of claim 72, wherein an amount of thephosphors in the pharmaceutical carrier ranges from 0.1 to 0.66milligrams of phosphor per cm³ of the volume of the diseased site, and aconcentration of the photoactivatable drug in the pharmaceutical carrierranges from 10 μg/mL to 50 μg/mL.
 76. The method of claim 72, whereindelivering comprises generating x-rays from a peak applied cathodevoltage at or below 300 kVp, at or below 200 kVp, at or below 120 kVp,at or below 105 kVp, at or below 80 kVp, at or below 70 kVp, at or below60 kVp, at or below 50 kVp, at or below 40 kVp, at or below 30 kVp, ator below 20 kVp, at or below 10 kVp, or at or below 5 kVp.
 77. Themethod of claim 72, wherein delivering comprises providing a dose ofx-rays in an amount to cause an auto-vaccine effect in the human oranimal body.
 78. The method of claim 72, wherein delivering comprisesproviding a booster treatment which repeats on a periodic basis atreatment of the diseased site.
 79. The method of claim 78, wherein, inthe booster treatment, at least one of phosphor concentration,photoactivatable drug concentration, and the radiation dose is increasedby a factor of at least two times, five times, or ten times respectiveinitial values.
 80. The method of claim 78, wherein the boostertreatment produces psoralen-modified cancer cells or X-ray modifiedcancer cells.
 81. The method of claim 78, wherein the booster treatmentproduces radiation damaged cancer cells.
 82. The method of claim 78,wherein a period between booster treatments is delayed according to atolerance level of the human or animal body for radiation- modifiedcells generated during the booster treatment.
 83. The method of claim72, wherein delivering comprises directing x-rays to at least one of atumor or a malignancy.
 84. The method of claim 72, wherein deliveringcomprises directing x-rays to at least one of a eukaryotic cell, aprokaryotic cell, a subcellular structure, an extracellular structure, avirus or prion, a cellular tissue, a cell membrane, a nuclear membrane,cell nucleus, nucleic acid, mitochondria, ribosome, or other cellularorganelle.
 85. The method of claim 72, wherein delivering comprisesdirecting x-rays to a diseased site in a pulsed manner having an on andoff time.
 86. The method of claim 85, wherein delivering comprisesdirecting x-rays to the diseased site such that the on time activatesthe phosphor and the off time is long enough for decay of phosphor lightemission.
 87. The method of claim 72, wherein delivering comprisesdirecting x-rays to a tumor or a malignancy in a pulsed manner having anon and off time.
 88. The method of claim 87, wherein deliveringcomprises directing x-rays to the tumor or the malignancy such that theon time activates the phosphor and the off time is long enough for decayof phosphor light emission.
 89. The method of claim 72, whereindelivering comprises directing x-rays to the diseased site according toa predetermined radiation protocol such that a predetermined changeoccurs in the diseased site.
 90. The method of claim 89, wherein saidpredetermined change comprises at least one of 1) affects a prion,viral, bacterial, fungal, or parasitic infection, 2) comprises at leastone of one of tissue regeneration, inflammation relief, pain relief,immune system fortification, or 3) comprises at least changes in cellmembrane permeability, up-regulation and down-regulation of adenosinetriphosphate and nitric oxide.
 91. The method of claim 72, whereindelivering comprises providing a dose of about 1 Gy using twenty onex-ray pulses spaced apart by 10 seconds; and, each x-ray pulse of 800 msis delivered from an x-ray source set at a voltage of 80 kV and anamperage of 200 mA.